View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2015	Nov. 03, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	Chemours Co
Entity Central Index Key	0001627223
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		180,984,614

Interim Combined Statements of Operations (Unaudited) - USD ($)
$ in Millions

3 Months Ended

9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Income Statement [Abstract]

Net sales

$ 1,486

$ 1,632

$ 4,357

$ 4,883

Cost of goods sold

1,222

1,273

3,615

3,824

Gross profit

264

359

742

1,059

Selling, general and administrative expense

157

176

481

532

Research and development expense

110

Employee separation and asset related charges, net

184

245

Goodwill impairment

Total expenses

384

209

819

663

Equity in earnings of affiliates

Interest expense

(51)

(79)

Other income, net

(13)

(Loss) income before income taxes

(107)

143

(67)

430

(Benefit from) provision for income taxes

(78)

(63)

108

Net (loss) income

(29)

108

(4)

322

Less: Net income attributable to noncontrolling interests

Net (loss) income attributable to Chemours

$ (29)

$ 107

$ (4)

$ 321

Per share data

Basic (loss) earnings per share of common stock (USD per share)

^[1]

$ (0.16)

$ 0.59

$ (0.02)

$ 1.77

Diluted (loss) earnings per share of common stock (USD per share)

^[1]

(0.16)

0.59

(0.02)

1.77

Dividends per share of common stock (USD per share)

$ 0.03

$ 0.00

$ 0.58

$ 0.00

[1]

1 On July 1, 2015, E. I. du Pont de Nemours and Company distributed 180,966,833 shares of Chemours' common stock to holders of its common stock. Basic and diluted (loss) earnings per common share for the three and nine months ended September 30, 2014 were calculated using the shares distributed on July 1, 2015. Refer to Note 9 for information regarding the calculation of basic and diluted earnings per share.

Interim Combined Statements of Operations (Unaudited) Interim Combined Statements of Operations (Unaudited) (Parenthetical) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Weighted-average number of common shares outstanding- Basic	180,968,049	180,966,833	180,968,049	180,966,833

Interim Consolidated Statements of Comprehensive (Loss) Income (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Statement of Comprehensive Income [Abstract]
Net (loss) Income, pre-tax	$ (107)	$ 143	$ (67)	$ 430
Net (loss) Income, tax	78	(35)	63	(108)
Net (loss) income	(29)	108	(4)	322
Foreign currency translation adjustment	(52)	0	(286)	0
Cumulative translation adjustment, tax	0	0	0	0
Cumulative translation adjustment, after-tax	(52)	0	(286)	0
Net gain (loss), pre-tax	(3)	0	0	0
Net gain (loss), tax	0	0	0	0
Net gain (loss), after-tax	(3)	0	0	0
Prior service benefit, pre-tax	17		17	0
Prior service benefit, tax	(2)		(2)	0
Prior service benefit, after-tax	15		15	0
Effect of foreign exchange rates, pre-tax	4	0	27	0
Effect of foreign exchange rates, tax	(1)	0	(7)	0
Effect of foreign exchange rates, after-tax	3	0	20	0
Amortization of prior service cost, pre-tax	1	0	3	0
Amortization of prior service cost, tax	0	0	0	0
Amortization of prior service cost, after tax	1	0	3	0
Amortization of loss, pre-tax	4	0	11	0
Amortization of loss, tax	(1)	0	(2)	0
Amortization of loss, after tax	3	0	9	0
Pension benefit plans, net, pre-tax	23	0	58	0
Pension benefit plans, net, tax	(4)	0	(11)	0
Pension benefit plans, net, after-tax	19	0	47	0
Other comprehensive loss, pre-tax	(29)	0	(228)	0
Other comprehensive loss, tax	(4)	0	(11)	0
Other comprehensive loss, after-tax	(33)	0	(239)	0
Comprehensive (loss) income, pre-tax	(136)	143	(295)	430
Comprehensive (loss) income, tax	74	(35)	52	(108)
Comprehensive (loss) income, after-tax	(62)	108	(243)	322
Comprehensive income (loss) attributable to noncontrolling Interests, pre-tax	0	0	0	(1)
Comprehensive income (loss) attributable to noncontrolling Interests, tax	0	0	0	0
Comprehensive income (loss) attributable to noncontrolling Interests, after-tax	0	0	0	(1)
Comprehensive (loss) income attributable to Chemours, pre-tax	(136)	143	(295)	431
Comprehensive (loss) income attributable to Chemours, tax	74	(35)	52	(108)
Comprehensive (loss) income attributable to Chemours, after-tax	$ (62)	$ 108	$ (243)	$ 323

Interim Combined Balance Sheets - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Assets
Cash	$ 215	$ 0
Accounts and notes receivable - trade, net	1,102	846
Inventories	993	1,052
Prepaid expenses and other	120	43
Deferred income taxes	51	21
Total current assets	2,481	1,962
Property, plant and equipment	9,043	9,282
Less: Accumulated depreciation	(5,873)	(5,974)
Net property, plant and equipment	3,170	3,308
Goodwill	169	198
Intangible assets, net	11	11
Investments in affiliates	154	124
Other assets	466	375
Total assets	6,451	5,978
Liabilities [Abstract]
Accounts payable	1,009	1,046
Current maturities of long-term debt	38	0
Deferred income taxes	14	9
Other accrued liabilities	444	352
Total current liabilities	1,505	1,407
Long-term debt	3,924	0
Other liabilities	553	464
Deferred income taxes	379	434
Total liabilities	6,361	2,305
Commitments and contingent liabilities
Stockholders' equity
Common stock (par value $.01 per share; 180,968,795 shares issued and outstanding as of September 30, 2015)	2	0
Additional paid in capital	645	0
DuPont Company Net Investment, prior to separation	0	3,650
Retained (deficit) earnings	(30)	0
Accumulated other comprehensive (loss) income	(531)	19
Total Chemours stockholders' equity	86	3,669
Noncontrolling interests	4	4
Total equity	90	3,673
Total liabilities and equity	$ 6,451	$ 5,978

Interim Consolidated Balance Sheet (Parenthetical)	Sep. 30, 2015 $ / shares shares
Statement of Financial Position [Abstract]
Common stock , par value (USD per share) \| $ / shares	$ 0.01
Common stock, shares Issued (in shares)	180,968,795
Common stock, shares outstanding (in shares)	180,968,795

Interim Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Millions	Total	Common Stock [Member]	Parent Company Net Investment [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Noncontrolling Interest [Member]	Retained Earnings [Member]
Shares, beginning balance at Dec. 31, 2013		0
Total stockholders' equity, beginning balance at Dec. 31, 2013	$ 3,217	$ 0	$ 3,195	$ 0	$ 19	$ 3	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	322		322
Net transfers to (from) DuPont	(365)		365
Foreign currency translation adjustment	0
Pension, net of tax benefit of $11	0
Shares, ending balance at Sep. 30, 2014		0
Total stockholders' equity, ending balance at Sep. 30, 2014	3,904	$ 0	3,882	0	19	3	0
Shares, beginning balance at Dec. 31, 2014		0
Total stockholders' equity, beginning balance at Dec. 31, 2014	3,673	$ 0	3,650	0	19	4	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	(4)		25				(29)
Establishment of pension plans, net and related accumulated other comprehensive income (loss)	(43)		268		(311)
Dividend declared	(105)		(100)	(5)
Non-cash debt exchange	507		(507)
Cash provided at separation by DuPont	247		247
Elimination of predecessor balances	(2,940)		(3,583)	643
Issuance of Common Stock at separation (in shares)		180,966,833
Issuance of Common Stock at separation		$ 2		(2)
Common Stock issued - compensation plans (in shares)		1,962
Foreign currency translation adjustment	(286)				(286)
Pension, net of tax benefit of $11	47				47
Stock based compensation expense	8			9			(1)
Shares, ending balance at Sep. 30, 2015		180,968,795
Total stockholders' equity, ending balance at Sep. 30, 2015	$ 90	$ 2	$ 0	$ 645	$ (531)	$ 4	$ (30)

Interim Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Statement of Stockholders' Equity [Abstract]
Net tax benefit	$ 4	$ 0	$ 11	$ 0

Interim Combined Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Operating activities
Net (loss) income	$ (4)	$ 322
Adjustments to reconcile net (loss) income to cash used for operating activities:
Depreciation and amortization	201	185
Other operating charges and credits, net	22	6
Equity in earnings of affiliates, net of dividends received of $0 and $1	(18)	(13)
Deferred tax benefit	(86)	(26)
Asset related charges	191	0
Accounts and notes receivable - trade, net	(250)	(189)
Inventories and other operating assets	(29)	(6)
Accounts payable and other operating liabilities	(147)	(266)
Cash (used for) provided by operating activities	(120)	13
Investing activities
Purchases of property, plant and equipment	(392)	(404)
Proceeds from sales of assets, net	8	27
Foreign exchange contract settlements	61	0
Investment in affiliates	(32)	0
Cash used for investing activities	(355)	(377)
Financing activities
Proceeds from issuance of debt, net	3,490	0
Debt repayments	(6)	0
Dividends paid	(100)	0
Debt issuance costs	(79)	0
Payments of long-term capital lease obligations	0	(1)
Cash provided at separation by DuPont	247	0
Net transfers (to) from DuPont	(2,857)	365
Cash provided by financing activities	695	364
Effect of exchange rate changes on cash	(5)	0
Increase in cash	215	0
Cash at beginning of period	0	0
Cash at end of period	215	0
SUPPLEMENTAL DISCLOSURE OF SIGNIFICANT NON-CASH INVESTING ACTIVITIES:
Change in property, plant and equipment included in accounts payable	$ (42)	$ (11)

Interim Combined Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Statement of Cash Flows [Abstract]
Dividends received	$ 0	$ 1

Background and Description of the Business	9 Months Ended
Background and Description of the Business	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background and Description of the Business	Background and Description of the Business The Chemours Company (Chemours) delivers customized solutions with a wide range of industrial and specialty chemical products for markets including plastics and coatings, refrigeration and air conditioning, general industrial, mining and oil refining. Principal products include titanium dioxide (TiO₂), refrigerants, industrial fluoropolymer resins, sodium cyanide, sulfuric acid and aniline. Chemours consists of three reportable segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. Chemours is globally operated with manufacturing facilities, sales centers, administrative offices and warehouses located throughout the world. Chemours' operations are primarily located in the United States (U.S.), Canada, Mexico, Brazil, the Netherlands, Belgium, China, Taiwan, Japan, Switzerland, Singapore, Hong Kong, India, the United Kingdom, France and Sweden. As of September 30, 2015, Chemours consists of 36 production facilities globally, five dedicated to Titanium Technologies, 17 dedicated to Fluoroproducts, 12 dedicated to Chemical Solutions and two that support multiple Chemours segments. Effective prior to the opening of trading on the New York Stock Exchange (NYSE) on July 1, 2015 (the Distribution Date), E. I. du Pont de Nemours and Company (DuPont) completed the previously announced separation of the businesses comprising DuPont’s Performance Chemicals reporting segment, and certain other assets and liabilities, into Chemours, a separate and distinct public company. The separation was completed by way of a distribution of all of the then-outstanding shares of common stock of Chemours through a dividend in kind of Chemours’ common stock (par value $0.01) to holders of DuPont common stock (par value $0.30) as of the close of business on June 23, 2015 (the Record Date) (the transaction referred to herein as the Distribution). On the Distribution Date, each holder of DuPont's common stock received one share of Chemours' common stock for every five shares of DuPont's common stock held on the Record Date. The spin-off was completed pursuant to a Separation Agreement and other agreements with DuPont related to the spin-off, including an Employee Matters Agreement, a Tax Matters Agreement, a Transition Services Agreement and an Intellectual Property Cross-License Agreement. These agreements govern the relationship between Chemours and DuPont following the spin-off and provided for the allocation of various assets, liabilities, rights and obligations. These agreements also include arrangements for transition services to be provided by DuPont to Chemours. Unless the context otherwise requires, references in these Notes to the Consolidated Financial Statements to "we," "us," "our," "Chemours" and the "Company" refer to The Chemours Company and its consolidated subsidiaries after giving effect to the Distribution. Basis of Presentation The accompanying Interim Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP) for interim financial information and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, all adjustments considered necessary for a fair statement of the results for interim periods have been included. Certain reclassifications of prior year's data have been made to conform to current period presentation. Results for interim periods should not be considered indicative of results for a full year. These Interim Consolidated Financial Statements do not represent complete financial statements and should be read in conjunction with the audited Combined Financial Statements for the years ended December 31, 2014, 2013 and 2012, collectively referred to herein as the “Annual Combined Financial Statements” in our Information Statement included in our Registration Statement. Unless otherwise stated, references to years and three and nine month periods relate to Chemours' fiscal years and three and nine month periods. The notes that follow are an integral part of the Interim Consolidated Financial Statements. Chemours did not operate as a separate, stand-alone entity for the full period covered by the Interim Consolidated Financial Statements. Prior to our spin-off on July 1, 2015, Chemours operations were included in DuPont's financial results in different legal forms, including but not limited to wholly-owned subsidiaries for which Chemours was the sole business, components of legal entities in which Chemours operated in conjunction with other DuPont businesses and a majority owned joint venture. For periods prior to July 1, 2015, the accompanying Interim Consolidated Financial Statements have been prepared from DuPont’s historical accounting records and are presented on a stand-alone basis as if the business operations had been conducted independently from DuPont. Prior to January 1, 2015, aside from a Japanese entity that is a dual-resident for U.S. federal income tax purposes, there was no direct ownership relationship among all the other various legal entities comprising Chemours. Prior to July 1, 2015, DuPont and its subsidiaries’ net investments in these operations is shown in lieu of Stockholder’s Equity in the Interim Consolidated Financial Statements. The Interim Consolidated Financial Statements include the historical operations, assets and liabilities of the legal entities that are considered to comprise the Chemours business, including certain environmental remediation and litigation obligations for which Chemours has indemnified DuPont. All of the allocations and estimates in the Interim Consolidated Financial Statements prior to July 1, 2015 are based on assumptions that management believes are reasonable. However, the Interim Consolidated Financial Statements included herein may not be indicative of the financial position, results of operations and cash flows of Chemours in the future or if Chemours had been a separate, stand-alone entity during the periods presented. The net transfers from DuPont on the Interim Consolidated Statements of Equity include a non-cash contribution from DuPont of $93 for the nine months ended September 30, 2015. This non-cash contribution occurred during physical separation activities at shared production facilities in the United States prior to the spin-off. It was determined that assets previously managed by other DuPont businesses would be transferred to and managed by Chemours.

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Background and Description of the Business The Chemours Company (Chemours) delivers customized solutions with a wide range of industrial and specialty chemical products for markets including plastics and coatings, refrigeration and air conditioning, general industrial, mining and oil refining. Principal products include titanium dioxide (TiO₂), refrigerants, industrial fluoropolymer resins, sodium cyanide, sulfuric acid and aniline. Chemours consists of three reportable segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. Chemours is globally operated with manufacturing facilities, sales centers, administrative offices and warehouses located throughout the world. Chemours' operations are primarily located in the United States (U.S.), Canada, Mexico, Brazil, the Netherlands, Belgium, China, Taiwan, Japan, Switzerland, Singapore, Hong Kong, India, the United Kingdom, France and Sweden. As of September 30, 2015, Chemours consists of 36 production facilities globally, five dedicated to Titanium Technologies, 17 dedicated to Fluoroproducts, 12 dedicated to Chemical Solutions and two that support multiple Chemours segments. Effective prior to the opening of trading on the New York Stock Exchange (NYSE) on July 1, 2015 (the Distribution Date), E. I. du Pont de Nemours and Company (DuPont) completed the previously announced separation of the businesses comprising DuPont’s Performance Chemicals reporting segment, and certain other assets and liabilities, into Chemours, a separate and distinct public company. The separation was completed by way of a distribution of all of the then-outstanding shares of common stock of Chemours through a dividend in kind of Chemours’ common stock (par value $0.01) to holders of DuPont common stock (par value $0.30) as of the close of business on June 23, 2015 (the Record Date) (the transaction referred to herein as the Distribution). On the Distribution Date, each holder of DuPont's common stock received one share of Chemours' common stock for every five shares of DuPont's common stock held on the Record Date. The spin-off was completed pursuant to a Separation Agreement and other agreements with DuPont related to the spin-off, including an Employee Matters Agreement, a Tax Matters Agreement, a Transition Services Agreement and an Intellectual Property Cross-License Agreement. These agreements govern the relationship between Chemours and DuPont following the spin-off and provided for the allocation of various assets, liabilities, rights and obligations. These agreements also include arrangements for transition services to be provided by DuPont to Chemours. Unless the context otherwise requires, references in these Notes to the Consolidated Financial Statements to "we," "us," "our," "Chemours" and the "Company" refer to The Chemours Company and its consolidated subsidiaries after giving effect to the Distribution. Basis of Presentation The accompanying Interim Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP) for interim financial information and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, all adjustments considered necessary for a fair statement of the results for interim periods have been included. Certain reclassifications of prior year's data have been made to conform to current period presentation. Results for interim periods should not be considered indicative of results for a full year. These Interim Consolidated Financial Statements do not represent complete financial statements and should be read in conjunction with the audited Combined Financial Statements for the years ended December 31, 2014, 2013 and 2012, collectively referred to herein as the “Annual Combined Financial Statements” in our Information Statement included in our Registration Statement. Unless otherwise stated, references to years and three and nine month periods relate to Chemours' fiscal years and three and nine month periods. The notes that follow are an integral part of the Interim Consolidated Financial Statements. Chemours did not operate as a separate, stand-alone entity for the full period covered by the Interim Consolidated Financial Statements. Prior to our spin-off on July 1, 2015, Chemours operations were included in DuPont's financial results in different legal forms, including but not limited to wholly-owned subsidiaries for which Chemours was the sole business, components of legal entities in which Chemours operated in conjunction with other DuPont businesses and a majority owned joint venture. For periods prior to July 1, 2015, the accompanying Interim Consolidated Financial Statements have been prepared from DuPont’s historical accounting records and are presented on a stand-alone basis as if the business operations had been conducted independently from DuPont. Prior to January 1, 2015, aside from a Japanese entity that is a dual-resident for U.S. federal income tax purposes, there was no direct ownership relationship among all the other various legal entities comprising Chemours. Prior to July 1, 2015, DuPont and its subsidiaries’ net investments in these operations is shown in lieu of Stockholder’s Equity in the Interim Consolidated Financial Statements. The Interim Consolidated Financial Statements include the historical operations, assets and liabilities of the legal entities that are considered to comprise the Chemours business, including certain environmental remediation and litigation obligations for which Chemours has indemnified DuPont. All of the allocations and estimates in the Interim Consolidated Financial Statements prior to July 1, 2015 are based on assumptions that management believes are reasonable. However, the Interim Consolidated Financial Statements included herein may not be indicative of the financial position, results of operations and cash flows of Chemours in the future or if Chemours had been a separate, stand-alone entity during the periods presented. The net transfers from DuPont on the Interim Consolidated Statements of Equity include a non-cash contribution from DuPont of $93 for the nine months ended September 30, 2015. This non-cash contribution occurred during physical separation activities at shared production facilities in the United States prior to the spin-off. It was determined that assets previously managed by other DuPont businesses would be transferred to and managed by Chemours.

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies The significant accounting policies are described in the Annual Combined Financial Statements in our Information Statement included in our Registration Statement. The following significant accounting policies have been updated during 2015. Foreign Currency Translation Chemours identifies its separate and distinct foreign entities and groups them into two categories: 1) extension of the parent (U.S. dollar functional currency) and 2) self-contained (local functional currency). If a foreign entity does not align with either category, factors are evaluated and a judgment is made to determine the functional currency. Chemours changes the functional currency of its separate and distinct foreign entities only when significant changes in economic facts and circumstances indicate clearly that the functional currency has changed. During the periods covered by the Interim Consolidated Financial Statements, part of the Chemours business operated within foreign entities. For foreign entities where the U.S. dollar is the functional currency, all foreign currency-denominated asset and liability amounts are remeasured into U.S. dollars at end-of-period exchange rates, except for inventories, prepaid expenses, property, plant and equipment, goodwill and other intangible assets, which are remeasured at historical rates. Foreign currency-denominated income and expenses are remeasured at average exchange rates in effect during the period, except for expenses related to balance sheet amounts remeasured at historical exchange rates. Exchange gains and losses arising from remeasurement of foreign currency-denominated monetary assets and liabilities are included in other income, net in the period in which they occur. For foreign entities where the local currency is the functional currency, assets and liabilities denominated in local currencies are translated into U.S. dollar at end-of-period exchange rates and the resulting translation adjustments are reported as a component of accumulated other comprehensive (loss) income in equity. Assets and liabilities denominated in other than the functional currency are remeasured into the functional currency prior to translation into U.S. dollars and the resulting exchange gains or losses are included in income in the period in which they occur. Income and expenses are translated into U.S. dollars at average exchange rates in effect during the period. Beginning in 2015, when the Chemours operations were legally and operationally separated within DuPont in anticipation of the spin-off, some of the resulting newly created Chemours foreign entities set their local currency as the functional currency. Employee Benefits Prior to separation, certain of Chemours’ employees participated in defined benefit pension and other post-employment benefit plans (the Plans) sponsored by DuPont and accounted for by DuPont in accordance with accounting guidance for defined benefit pension and other post-employment benefit plans. Substantially all expenses related to these plans were allocated in shared entities and reported within costs of goods sold, selling, general and administrative expenses and research and development expense in the Interim Consolidated Statements of Operations. Chemours considered all plans to be part of a multi-employer plan with DuPont prior to January 1, 2015. In connection with the spin-off, Chemours retained the existing Netherlands pension plan and an agreement was executed in 2015 to ensure continuance of the plan for both DuPont and Chemours employees and retirees. As a result of that agreement, Chemours now accounts for the Netherlands plan as a multiple employer plan. Additionally, in 2015, Chemours formed new pension plans in Taiwan, Germany, Belgium, Switzerland, Japan, Korea and Mexico that mirror the plans historically operated by DuPont in these countries. The new plans are accounted for under the single employer method. See Note 18 for additional information. Derivatives Prior to 2015, Chemours participated in DuPont’s foreign currency hedging program to reduce earnings and cash flow volatility associated with foreign currency exchange rate changes. DuPont formally documented the hedge relationships, including identification of the hedging instruments and the hedged items, the risk management objectives and strategies for undertaking the hedge transactions and the methodologies used to assess effectiveness and measure ineffectiveness. Realized gains and losses on derivative instruments of DuPont were allocated by DuPont to Chemours based on projected exposure. Chemours recognized its allocable share of the gains and losses on DuPont’s derivative financial instruments in earnings when the forecasted sales occurred for foreign currency hedges. The foreign currency hedges qualified as cash flow hedges, and the realized gains recognized in earnings were less than $1 for the three and nine months ended months ended September 30, 2014. Chemours’ participation in this program terminated as of January 1, 2015. Beginning in February 2015, Chemours began entering into forward currency exchange contracts to minimize volatility in earnings related to the foreign exchange gains and losses resulting from remeasuring net monetary assets that Chemours holds which are denominated in non-functional currencies. Chemours does not hold or issue financial instruments for speculative or trading purposes. The derivative assets and liabilities are reported on a gross basis in the Interim Consolidated Balance Sheets. All gains and losses resulting from the revaluation of the derivative assets and liabilities are recognized in other income, net in the Interim Consolidated Statements of Operations during the period in which they occurred. Please refer to Note 17 for additional information. Fair Value Measurement Under the accounting for fair value measurements and disclosures, a fair value hierarchy was established that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical asset and liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Chemours uses the following valuation techniques to measure fair value for its assets and liabilities: (a) Level 1—Quoted market prices in active markets for identical assets and liabilities (b) Level 2—Significant other observable inputs (e.g. quoted prices for similar items in active markets, quoted prices for identical or similar items in markets that are not active, inputs other than quoted prices that are observable, such as interest rate and yield curves, and market-corroborated inputs); and (c) Level 3—Unobservable inputs for the asset or liability, which are valued based on management's estimates of assumptions that market participants would use in pricing the asset or liability. Recent Accounting Pronouncements In June 2015, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2015-11, "Inventory (Topic 330), Simplifying the Measurement of Inventory," which requires an entity to measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Currently, the inventory standard requires an entity to measure inventory at the lower of cost or market. Market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. The amendment does not apply to inventory that is measured using last-in, first-out (LIFO) or the retail inventory method but apply to all other inventory, which includes inventory that is measured using first-in, first-out (FIFO) or average cost. The amendment is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, and should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. Chemours is currently evaluating the impact of adopting this guidance. In May 2015, the FASB issued ASU No. 2015-07, "Fair Value Measurement (Topic 820) - Disclosures for Investment in Certain Entities that Calculate Net Asset Value per Share or its Equivalent." This guidance removes the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient. The guidance also removes the requirement to make certain disclosures for all investments that are eligible to be measured at fair value using the net asset value per share practical expedient. Rather, those disclosures are limited to investments for which the entity has elected to measure the fair value using that practical expedient. The amendment is effective for fiscal years beginning after December 15, 2015 and interim periods within those fiscal years. A reporting entity should apply the amendments retrospectively to all periods presented and earlier application is permitted. Chemours is currently evaluating the impact of adopting this guidance. In April 2015, the FASB issued ASU 2015-05, "Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement," which provides guidance about whether a cloud computing arrangement includes a software license. The customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If the cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. This guidance is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2015, and early adoption is permitted. Chemours is currently evaluating the impact of adopting this guidance. In April 2015, the FASB issued ASU No. 2015-03, “Interest — Imputation of Interest (Subtopic 835-30),” which requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The guidance is effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015 with early adoption permitted, including adoption in an interim period. Chemours adopted this guidance for the quarter ending June 30, 2015. The adoption of this standard has no impact on Chemours’ results of operations or cash flows. Due to the accounting change described above, Chemours recorded debt issuance costs incurred for the issuance of its senior secured term loans and senior unsecured notes as a reduction of the liability on the Interim Consolidated Balance Sheets. See Note 15 for additional information. In February 2015, the FASB issued ASU No. 2015-02, “Consolidation (Topic 810): Amendments to the Consolidation Analysis.” The amendments modify the evaluation of whether limited partnerships and similar legal entities are variable interest entities (VIEs) or voting interest entities and eliminate the presumption that a general partner should consolidate a limited partnership. The amendment is effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. A reporting entity also may apply the amendments retrospectively. Chemours is currently evaluating the impact of adopting this guidance on its financial position and results of operations. In May 2014, the FASB and the International Accounting Standards Board (IASB) jointly issued ASU No. 2014-09, "Revenue from Contracts with Customers (Topic 606)," which clarifies the principles for recognizing revenue and develops a common revenue standard for GAAP and International Financial Reporting Standards (IFRS). The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The guidance is effective for public entities for annual and interim periods beginning after December 15, 2016 (original effective date). In July 2015, the FASB approved a deferral of the effective date of this guidance to provide entities with adequate time to effectively implement the new revenue standard and adoption as of the original effective date is permitted. The Company is currently evaluating the impact of adopting this guidance on its financial position and results of operations. In April 2014, the FASB issued ASU No. 2014-08, “Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity,” amending existing requirements for reporting discontinued operations and disposals of components of an entity. The amended guidance limits the discontinued operations reporting to disposal transactions that represent strategic shifts having a major effect on operations and financial results. The amendment also enhances disclosures and requires assets and liabilities of a discontinued operation to be classified as such for all periods presented in the financial statements. Chemours adopted this guidance effective on January 1, 2015. Due to the change in requirements for reporting discontinued operations described above, presentation and disclosures of future disposal transactions after adoption may be different than under current standards.

Relationship with DuPont and Related Entities

9 Months Ended

Sep. 30, 2015

Relationship with DuPont and Related Entities

Prior to the spin-off on July 1, 2015, Chemours was managed and operated in the normal course of business with other affiliates of DuPont. Accordingly, certain shared costs were allocated to Chemours and reflected as expenses in the stand-alone Interim Consolidated Financial Statements. Management of DuPont and Chemours considered the allocation methodologies used to be reasonable and appropriate reflections of the historical DuPont expenses attributable to Chemours for purposes of the stand-alone financial statements. The expenses reflected in the Consolidated Financial Statements may not be indicative of expenses that will be incurred by Chemours in the future. All related party transactions approximated market prices.

Subsequent to July 1, 2015, DuPont was no longer a related party of Chemours. Accordingly, beginning July 1, 2015, sales to DuPont businesses are reflected in net sales in our Interim Consolidated Statement of Operations. Purchases of by-products from DuPont businesses are reflected in cost of goods sold in our Interim Consolidated Statements of Operations. Chemours ongoing relationship with DuPont is governed by a Separation Agreement and other agreements with DuPont related to the spin-off, including an Employee Matters Agreement, a Tax Matters Agreement, a Transition Services Agreement and an Intellectual Property Cross-License Agreement. These agreements provided for the allocation of various assets, liabilities, rights and obligations, and include arrangements for transition services to be provided by DuPont to Chemours.

(a) Related Party Purchases and Sales

Prior to the spin-off, including certain periods covered by the Interim Consolidated Financial Statements, Chemours sold finished goods to DuPont and its non-Chemours businesses.

Related party sales to DuPont include the following amounts:



Selling Segment	Three months ended September 30,					Nine months ended September 30,
Selling Segment	2015			2014		2015			2014
Titanium Technologies	$	—	¹	$	1	$	2	¹	$	1
Fluoroproducts	—		¹	10		34		¹	34
Chemical Solutions	—		¹	14		21		¹	55
Total	$	—		$	25	$	57		$	90

¹ Subsequent to the spin-off on July 1, 2015, transactions with DuPont businesses were not considered related party transactions.

(b) Leveraged Services and Corporate Costs

Prior to the spin-off on July 1, 2015, DuPont incurred significant corporate costs for services provided to Chemours as well as other DuPont businesses. These costs included expenses for information systems, accounting, other financial services such as treasury and audit, purchasing, human resources, legal, facilities, engineering, corporate research and development, corporate stewardship, marketing and business analysis support.

A portion of these costs benefited multiple or all DuPont businesses, including Chemours, and were allocated to Chemours and its reportable segments using methods based on proportionate formulas involving total costs or other various allocation methods that management considered consistent and reasonable. Other Chemours corporate costs are not allocated to the reportable segments and are reported in Corporate and Other.

The allocated leveraged functional service expenses and general corporate expenses included in the Interim Consolidated Statements of Operations were $0 and $238 for the three and nine months ended September 30, 2015, respectively, and $121 and $378 for the three and nine months ended September 30, 2014, respectively. Allocated leveraged functional service expenses and general corporate expenses were recorded in the Interim Consolidated Statements of Operations within the following captions:



	Three months ended September 30,					Nine months ended September 30,
	2015			2014		2015			2014
Selling, general and administrative expense	$	—	¹	$	105	$	205	¹	$	318
Research and development expense	—		¹	8		10		¹	35
Cost of goods sold	—		¹	8		23		¹	25
Total	$	—		$	121	$	238		$	378

¹Subsequent to the spin-off on July 1, 2015, transactions with DuPont businesses were not considered related party transactions. Accordingly, no costs were allocated after the July 1, 2015 spin-off date.

For a portion of the periods presented, Chemours participated in DuPont’s centralized cash management and financing programs. Disbursements were made through centralized accounts payable systems which were operated by DuPont. Cash receipts were transferred to centralized accounts, also maintained by DuPont. As cash was disbursed and received by DuPont, it was accounted for by Chemours through DuPont Company Net Investment.

During the third quarter of 2015, Chemours recorded a payable to DuPont in accounts payable in our Interim Consolidated Balance Sheets which represents the amount of cash at spin-off in excess of the target amount pursuant to the Separation Agreement. We expect to pay $49 by December 31, 2015. Additionally, the companies are still finalizing the reconciliation of working capital and other accounts and the net amount due to/from DuPont will be settled in accordance with the Separation Agreement.

(d) Tax Matters Agreement

Chemours and DuPont entered into a Tax Matters Agreement that governs the parties’ respective rights, responsibilities and obligations with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings and other matters regarding taxes. In general, under the agreement, DuPont is responsible for any U.S. federal, state and local taxes (and any related interest, penalties or audit adjustments) reportable on a consolidated, combined or unitary return that includes DuPont or any of its subsidiaries and Chemours and/or any of its subsidiaries for any periods or portions thereof ending on or prior to the date of the Separation and Chemours is responsible for any U.S. federal, state, local and foreign taxes (and any related interest, penalties or audit adjustments) that are imposed on Chemours and/or any of its subsidiaries for all tax periods, whether before or after the date of the distribution.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

Research and Development Expense	9 Months Ended
Research and Development Expense	Sep. 30, 2015
Research and Development [Abstract]
Research and Development Expense	Research and Development Expense Research and development expense directly incurred by Chemours was $18 and $58 for the three and nine months ended September 30, 2015, respectively, and $25 and $75 for the three and nine months ended September 30, 2014, respectively. Research and development expense also includes $0 and $10 for the three and nine months ended September 30, 2015, respectively, and $8 and $35 for the three and nine months ended September 30, 2014, respectively, which represents an assignment of costs associated primarily with DuPont’s Corporate Central Research and Development long-term research activities. This assignment was based on the cost of research projects for which Chemours was determined to be the sponsor or co-sponsor. All research services provided by DuPont’s Central Research and Development to Chemours were specifically requested by Chemours, covered by service-level agreements and billed based on usage. DuPont research and development services were no longer used after separation on July 1, 2015.

- Definition

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

+ References + Details

Employee Separation and Asset Related Charges, Net

9 Months Ended

Sep. 30, 2015

Restructuring Charges [Abstract]

Employee Separation and Asset Related Charges, Net

For the three and nine months ended, Chemours recorded charges for employee separation and asset related charges as follows:



	Three months ended September 30,				Nine months ended September 30,
	2015		2014		2015		2014
Employee Separation Charges	$	17	$	—	$	78	$	21
Asset Related Charges - Restructuring	122		—		122		—
Asset Related Charges - Impairment ¹	45		—		45		—
Total	$	184	$	—	$	245	$	21

¹ See Note 12 for further information.

Transformation Plan

During the third quarter of 2015, Chemours announced a plan to transform the company by reducing structural costs, growing market positions, optimizing its portfolio, refocusing investments, and enhancing its organization. Chemours expects the transformation plan will deliver $500 of Adjusted EBITDA improvement by 2017. Through a combination of higher free cash flow from operations, lower capital spending, and potential proceeds from asset sales, the Company anticipates reducing its leverage (net debt to Adjusted EBITDA) to approximately three times by year-end 2017. Key actions initiated under the Transformation Plan during the quarter included Titanium Technologies plant and production line closures, Fluoroproduct line closures and other cost reduction initiatives.

Titanium Technologies Plant Closures: In August 2015, the Company announced its plan to close its Edge Moor, DE manufacturing site located in the United States. The Edge Moor plant produced TiO₂ product for use in the paper industry and other applications where demand has steadily declined, resulting in underused capacity at the plant. In addition, as part of the plan, the Company permanently shut down one underused TiO₂production line at its New Johnsonville, TN plant in the U.S. The Company stopped production at Edge Moor in September 2015 and immediately began decommissioning the plant. The Company expects to complete decommissioning activities in first quarter of 2016 and will begin dismantling thereafter. Dismantling and removal activities are expected to be completed in early 2017.

As a result, in the third quarter of 2015, the Company recorded charges of approximately $126, which consist of property, plant and equipment and other asset impairment charges of $114 and employee separation costs of $12. These charges were allocated to the Titanium Technology segment. The Company also expects to incur additional charges for decommissioning, dismantling and removal costs from fourth quarter 2015 to early 2017, which will be expensed as incurred.

Fluoroproducts Restructuring: During the third quarter of 2015, in connection with the Company’s transformation plan announced in August 2015 and efforts to improve the profitability of the Fluoroproducts segment, management approved the shutdown of certain production lines of the segment’s manufacturing facilities in the United States. As a result, the Company recorded restructuring charges of approximately $10, which consist of property, plant and equipment accelerated depreciation of $8 and employee separation costs of $2.

Global Restructuring Programs

In 2015, in light of continued weakness in the global titanium dioxide market cycle and continued foreign currency impacts due to the strengthening of the U.S. dollar, Chemours accelerated implementation of its near-term priorities to drive operational and functional effectiveness to achieve both manufacturing and selling, general and administrative fixed cost improvements. Accordingly, in the second quarter of 2015, Chemours implemented a restructuring plan to reduce and simplify its cost structure. We recorded a pre-tax charge of $3 and $64 for employee separation costs in the three and nine months ended September 30, 2015. The actions associated with this charge and all related payments are expected to be substantially complete by the end of 2016 and are expected to result in future cash payments of approximately $41 related to severance and benefits.

In 2014, Chemours implemented a restructuring plan to increase productivity and recorded a pre-tax charge of $19 related to this initiative. The charge consisted of $16 related to employee separation costs and $3 for asset shut-down costs. The actions associated with this charge and all related payments are expected to be substantially complete by December 31, 2015.

The charges related to our programs and impairments impacted 2015 segment earnings as follows:



For the three months ended September 30, 2015	Titanium Technologies	Fluoroproducts	Chemical Solutions	Total
Titanium Technologies Plant Closures	126	—	—	126
Fluoroproducts Restructuring	—	10	—	10
PP&E impairment ¹	—	—	45	45
2015 Restructuring	1	1	1	3
Total	127	11	46	184

¹ See Note 12 for further information.



For the nine months ended September 30, 2015	Titanium Technologies	Fluoroproducts	Chemical Solutions	Total
Titanium Technologies Plant Closures	126	—	—	126
Fluoroproducts Restructuring	—	10	—	10
PP&E impairment	—	—	45	45
2015 Restructuring	24	26	14	64	¹
Total	150	36	59	245

¹ Includes approximately $13 related to Corporate overhead functions that was allocated to our segments.

For the nine months ended September 30, 2014, segment earnings were impacted by the 2014 restructuring program as shown in the following table. There were no restructuring charges to segment earnings in the three months ended September 30, 2014.



For the nine months ended September 30, 2014	Titanium Technologies		Fluoroproducts		Chemical Solutions		Total
2014 Restructuring	$	3	$	16	$	—	$	19

The following table shows the change in the liability account balance associated with our restructuring programs.



	Titanium Technologies Site Closures		Fluoroproducts		2015 Restructuring			2014 Restructuring			Total
Balance as of December 31, 2014	$	—	$	—	$	—		$	12		$	12
Charges to income for the nine months ended September 30, 2015	12		2		64			—			78
Charges to liability accounts:
Payments ¹	—		—		(23		)	(11		)	(34		)
Net currency translation adjustment ²	—		—		—			—			—
Balance as of September 30, 2015	$	12	$	2	$	41		$	1		$	56

¹Payments of $15 and $2 were made related to the 2015 and 2014 restructuring programs during the three months ended September 30, 2015, respectively. For the nine months ended September 30, 2015, payments of $23 and $11 were made related to the 2015 and 2014 restructuring programs, respectively. As of September 30, 2015, no payments were made for the Titanium Technologies plant closures.

²Net currency translation adjustment was less than $1 for all periods presented.

Other Income, Net

9 Months Ended

Sep. 30, 2015

Other Income and Expenses [Abstract]

Other Income, Net



	Three months ended September 30,					Nine months ended September 30,
	2015		2014			2015		2014
Leasing, contract services and miscellaneous income ¹	$	10	$	6		$	14	$	11
Royalty income²	3		13			10		22
Gain on sale of assets and businesses ³	—		1			—		12
Exchange gains (losses), net ⁴	44		(33		)	47		(29		)
Total other income, net	$	57	$	(13	)	$	71	$	16

¹Leasing, contract services and miscellaneous income includes accrued interest related to unrecognized tax benefits.

² Royalty income is primarily for technology and trademark licensing.

³Gain on sale of assets and businesses primarily relates to a sale of assets in the Fluoroproducts segment.

⁴Chemours uses foreign currency exchange derivatives to offset its net exposure, by currency, related to its non-functional currency-denominated monetary assets and liabilities. The objective of this program is to maintain an approximately balanced position in non-functional currencies in order to minimize, on an after-tax basis, the effects of exchange rate changes on net monetary asset positions. The pre-tax exchange gains are recorded in other income, net and the related tax impact is recorded in provision for income taxes on Chemours' Interim Consolidated Statements of Operations. The $44 net exchange gain for the three months ended September 30, 2015 includes a gain on derivative contracts of $66, partially offset by a $22 pre-tax exchange loss on non-functional monetary assets and liabilities as a result of the strengthening of the U.S. dollar against the Mexican peso, Chinese yuan, Euro and Brazilian real. The $47 net exchange gain for the nine months ended September 30, 2015 includes a gain on derivatives of $78, partially offset by a $31 pre-tax exchange loss on non-functional monetary assets and liabilities as a result of the strengthening of the U.S. dollar against the Mexican peso, Chinese yuan, Euro and Brazilian real.

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Chemours recorded a tax benefit of $78 and $63 for the three and nine months ended September 30, 2015, respectively, and a provision of $35 and $108 for the three and nine months ended September 30, 2014, respectively. Each year, Chemours and/or its subsidiaries, files income tax returns in the U.S. federal jurisdiction and various states and non-U.S. jurisdictions. These tax returns are subject to examination and possible challenge by the taxing authorities. Positions challenged by the taxing authorities may be settled or appealed by Chemours and/or DuPont in accordance with the Tax Matters Agreement. As a result, income tax uncertainties are recognized in Chemours’ Interim Consolidated Financial Statements in accordance with accounting for income taxes, when applicable. It is reasonably possible that changes to Chemours' global unrecognized tax benefits could be significant; however, due to the uncertainty regarding the timing of completion of audits and possible outcomes, a current estimate of the range of such changes that may occur within the next twelve months cannot be made. During the third quarter, in connection with the spin-off, the Company deemed approximately $1,300 of unremitted earnings of subsidiaries outside the U.S. as indefinitely reinvested. No deferred tax liability has been recognized with regard to the remittance of such earnings. It is not practical to estimate the income tax liability that might be incurred if such earnings were remitted to the U.S.

Accounts and Notes Receivable - Trade, Net

9 Months Ended

Sep. 30, 2015

Receivables [Abstract]

Accounts and Notes Receivable - Trade, Net

Accounts and Notes Receivable – Trade, Net



	September 30, 2015		December 31, 2014
Accounts receivable—trade, net ¹	$	969	$	746
VAT, GST and other taxes ²	88		62
Advances and deposits	13		15
Leases receivable—current	13		12
Notes receivable—trade ³	19		11
Total	$	1,102	$	846

¹Accounts receivable – trade is net of allowances of $4 and $4 as of September 30, 2015 and December 31, 2014, respectively. Allowances are equal to the estimated uncollectible amounts.

²Value Added Tax (VAT) and Goods and Services Tax (GST) receivables are generally recorded at the legal entity level and allocated to Chemours within shared legal entities.

³Notes receivable – trade primarily consists of $9 of derivative assets and loan receivables with terms of one year or less which are primarily concentrated in China. As of September 30, 2015, there were no past due notes receivable, nor were there any impairments related to current loan agreements.

Accounts and notes receivable are carried at amounts that approximate fair value. Bad debt expense was less than $1 for the three and nine months ended September 30, 2015. Bad debt expense was less than $1 for the three and nine months ended September 30, 2014.

Direct Financing Leases

At two of its facilities in the U.S. (Borderland and Morses Mill), Chemours has constructed fixed assets on land that it leases from third parties. Management has analyzed these arrangements and determined these assets represent a direct financing lease, whereby Chemours is the lessor of this equipment. Chemours has recorded leases receivable of $141 and $149 at September 30, 2015 and December 31, 2014 respectively, which represent the balance of the minimum future lease payments receivable. The current portion of leases receivable is included in accounts and notes receivable - trade, net, as shown above. The long-term portion of leases receivable are included in other assets, as shown in Note 14. Management has evaluated the realizable value of these leased assets and determined no impairment existed at September 30, 2015 or December 31, 2014. There is no estimated future residual value of these leased assets.

Earnings Per Share of Common Stock

9 Months Ended

Sep. 30, 2015

Earnings Per Share [Abstract]

Earnings Per Share of Common Stock

The table below shows a reconciliation of the numerator and denominator for basic and diluted earnings per share calculations for the periods indicated.



	Three months ended September 30,						Nine months ended September 30,
	2015			2014			2015			2014
Numerator:
Income from continuing operations attributable to Chemours	$	(29	)	$	107	¹	$	(4	)	$	321	¹
Denominator:
Weighted-average number of common shares outstanding- Basic	180,968,049			180,966,833			180,968,049			180,966,833
Dilutive effect of the company's employee compensation plans²	—			—			—			—
Weighted average number of common shares outstanding - Diluted	180,968,049			180,966,833			180,968,049			180,966,833

¹ 2014 amounts do not reflect interest expense on approximately $4,003 of debt issued during the second quarter of 2015 in connection with the spin-off. See Note 15 for additional information.

²Diluted earnings (loss) per share is calculated using net income (loss) available to common shareholders divided by diluted weighted-average shares of common shares outstanding during each period, which includes unvested restricted shares. Diluted earnings per share considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would have an anti-dilutive effect.

The following average number of stock options were antidilutive and, therefore, were not included in the diluted earnings per share calculation:



	Three months ended September 30,		Nine months ended September 30,
	2015	2014	2015	2014
Average number of stock options	8,401,821	—	8,401,821	—

Inventories

9 Months Ended

Sep. 30, 2015

Inventory, Net [Abstract]

Inventories



	September 30, 2015			December 31, 2014
Finished products	$	662		$	611
Semi-finished products	186			173
Raw materials, stores and supplies	395			521
Subtotal	1,243			1,305
Adjustment of inventories to a last-in, first-out (LIFO) basis	(250		)	(253		)
Total	$	993		$	1,052

Inventory values, before LIFO adjustment, are generally determined by the average cost method, which approximates current cost. Inventories are valued under the LIFO method at substantially all of the U.S. locations, which comprised $719 and $684 or 58% and 52% of inventories before the LIFO adjustments at September 30, 2015 and December 31, 2014, respectively. The remainder of inventory held in international locations and certain U.S. locations is valued under the average cost method.

Property, Plant, and Equipment	9 Months Ended
Property, Plant, and Equipment	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment Depreciation expense amounted to $69 and $198 for the three and nine months ended September 30, 2015, respectively and $56 and $183 for the three and nine months ended September 30, 2014, respectively. Property, plant and equipment includes gross assets under capital leases of $7 at September 30, 2015 and $6 at December 31, 2014. We evaluate long-lived assets and finite-lived identifiable intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset groupings may not be recoverable. When undiscounted future cash flows are not expected to be sufficient to recover an asset’s carrying amount, the asset is written down to its fair value based on a discounted cash flow analysis utilizing market participant assumptions. During the three months ended September 30, 2015, in connection with the strategic evaluation of the Chemical Solutions portfolio, excluding cyanides, the Company determined that a Chemical Solutions manufacturing facility’s carrying value may not be recoverable given the strategic decision to discontinue investment in the business. An impairment evaluation was performed which indicated that the carrying amount of this asset group in the U.S. was not recoverable when compared to the expected undiscounted cash flows. Based on management’s assessment of the fair value of the asset group, the Company determined that the carrying value of that asset group exceeded the fair value and as a result, a $45 pre-tax impairment charge was recorded in the Chemical Solutions segment. The fair value of the asset group was determined using an income approach based on the present value of the estimated future cash flows. The key assumptions used included growth rates and cash flow projections, discount rate, tax rate and an estimated terminal value. The amount was recorded in employee separation and asset related charges, net in the Interim Consolidated Statement of Operations. Refer to Note 6 for additional information.

Goodwill and Intangible Assets, Net

9 Months Ended

Sep. 30, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets, Net

Goodwill: The following table summarizes changes in the carrying amount of goodwill by reportable segment as of September 30, 2015:



	Titanium Technologies		Fluoroproducts		Chemical Solutions			Total
Balance as of December 31, 2014	$	13	$	85	$	100		$	198
Impairment charge	—		—		(25		)	(25		)
Other adjustments	—		—		(4		)	(4		)
Balance as of September 30, 2015	$	13	$	85	$	71		$	169

In the third quarter of 2015, in connection with the strategic evaluation of the Chemical Solutions portfolio, the Company realigned the reporting structure of the portfolio, specifically the level at which segment management regularly reviews operating results. The Company now identifies seven reporting units for purposes of goodwill allocation and impairment assessment. These seven reporting units are Aniline, Clean & Disinfect, Cyanides, Methylamines, Reactive Metal Solutions, Sulfur, and Vazo. Chemical Solutions remains an operating segment.

In addition, in connection with the spin-off on July 1, 2015, the Fluoroproducts reportable segment changed its organizational structure, which changed its reporting units from Fluorochemicals and Fluoropolymers to Fluorochemicals, Industrial Resins and Diversified Technologies, each of which is an operating segment. For reporting purposes, the three operating segments are aggregated into one reportable segment due to similar operating characteristics.

The reporting unit changes in Chemical Solutions and Fluoroproducts did not impact our reportable segments.

As a result of the changes discussed above, management allocated the historical goodwill of Fluoropolymers and Chemical Solutions to their new reporting units based on relative fair value.

Chemours tests goodwill for impairment at least annually on October 1; however, impairment tests are performed more frequently when events or changes in circumstances indicate that the asset may be impaired. Impairment exists when carrying value exceeds fair value. Evaluating goodwill for impairment is a two-step process. In the first step, Chemours compares the carrying value of net assets to the fair value of the related operations. If the fair value is determined to be less than the carrying value, a second step is performed to compute the amount of the impairment. In connection with the goodwill allocation to the new reporting units and strategic evaluation of Chemical Solutions, we evaluated the reporting units for impairment and determined that the estimated fair values of those reporting units, except for the Sulfur reporting unit, were substantially in excess of the carrying value, indicating that goodwill was not impaired. We performed the second step of the impairment test for Sulfur and determined that the implied fair value of goodwill was lower than its carrying value, resulting in a full impairment of the Sulfur reporting unit's goodwill. As a result, Chemours recorded a $25 million pre-tax impairment charge for goodwill during the quarter ended September 30, 2015 in the Chemicals Solutions segment.

Chemours estimates the fair value of its reporting units using the income approach based on the present value of estimated future cash flows, discounted at a risk-adjusted market rate, including a growth rate to calculate the terminal value. The Company’s forecasted future cash flows, which incorporate anticipated future revenue growth and related expenses to support the growth, were used to calculate fair value. The factors considered in determining the cash flows include: 1) macroeconomic conditions; 2) industry and market considerations; 3) costs of raw materials, labor or other costs having a negative effect on earnings and cash flows; 4) overall financial performance; and 5) other relevant entity-specific events. The discount rate used represents the weighted average cost of capital for the reporting units considering the risks and uncertainty inherent in the cash flows of the reporting units and in the internally developed forecasts. The implied fair value of the goodwill in step two was determined by allocating the fair value of the reporting units to all of the assets and liabilities as if the reporting units had been acquired in a business combination and its fair value was the purchase price paid to be acquired. The use of these unobservable inputs resulted in the fair value estimate being classified as a Level 3 asset measured at fair value on a nonrecurring basis subsequent to its original recognition.

The determination of whether or not goodwill is impaired involves a significant level of judgment in the assumptions underlying the approaches used to determine the estimated fair value of our reporting units. Chemours believes that assumptions and rates used in the impairment assessment are reasonable. However, these assumptions are judgmental and variations in any assumptions could result in materially different calculations of fair value. The Company will continue to evaluate goodwill on an annual basis as of October 1, and whenever events or changes in circumstances, such as significant adverse changes in operating results, market conditions or changes in management’s business strategy, indicate that there may be a probable indicator of impairment. It is possible that the assumptions used by management related to the evaluation may change or that actual results may vary significantly from management’s estimates.

Intangible Assets, Net: The following table summarizes the gross carrying amounts and accumulated amortization of other intangible assets by major class:



	September 30, 2015							December 31, 2014
	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Customer lists	$	20	$	(17	)	$	3	$	19	$	(16	)	$	3
Patents	20		(17		)	3		20		(16		)	4
Purchased trademarks	18		(15		)	3		18		(14		)	4
Purchased and licensed technology	20		(18		)	2		17		(17		)	—
Total	$	78	$	(67	)	$	11	$	74	$	(63	)	$	11

The aggregate pre-tax amortization expense for definite-lived intangible assets was $1 and $3 for the three and nine months ended September 30, 2015 and $1 and $2 for the three and nine months ended September 30, 2014, respectively. Definite-lived intangible assets are amortized over their estimated useful lives, generally for periods ranging from 5 to 20 years. The reasonableness of the useful lives of these assets is continually evaluated. There are no material indefinite-lived intangible assets.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Other Assets

9 Months Ended

Sep. 30, 2015

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Other Assets



	September 30, 2015		December 31, 2014
Leases receivable - non-current¹	$	128	$	137
Capitalized repair and maintenance costs	133		185
Pension assets ²	132		—
Advances and deposits	4		17
Deferred income taxes - non-current	30		9
Miscellaneous ³	39		27
Total	$	466	$	375

¹Leases receivable includes direct financing leases of property at two locations. See Note 10 for further information.

²Pension assets represent pension plans commencing in 2015. See Note 18 for further information.

³Miscellaneous includes prepaid expenses for royalty fees, vendor supply agreements and taxes other than income taxes, deferred financing fees related to the Revolving Credit Facility of $22, as well as capitalized expenses for the preparation of future landfill cells at Titanium Technologies’ New Johnsonville plant site.

Debt

9 Months Ended

Sep. 30, 2015

Debt Disclosure [Abstract]

Debt

In conjunction with Chemours' separation from DuPont, Chemours entered into approximately $4,003 of financing transactions on May 12, 2015. Long-term debt, net of an unamortized discount on the Term Loan Facility of $7, was comprised of the following at September 30, 2015:



	September 30, 2015
Long-term debt:
Senior secured term loan, net of issue discount	$	1,489
Senior unsecured notes:
6.625%, due May 2023	1,350
7.00%, due May 2025	750
6.125%, due May 2023 (€360)	403
Other	26
Total	4,018
Less: Unamortized debt issuance costs	56
Less: Current maturities	38
Total long-term debt	$	3,924

Senior Secured Credit Facilities

On May 12, 2015, Chemours entered into a credit agreement that provides for a seven-year senior secured term loan (the Term Loan Facility) in a principal amount of $1,500 repayable in equal quarterly installments at a rate of one percent of the original principal amount per year, with the balance payable on the final maturity date. The Term Loan Facility was issued with a $7 original issue discount and bears variable interest rate subject to a floor of 3.75%. The proceeds from the Term Loan Facility were used to fund a portion of the distribution to DuPont, along with related fees and expenses.

The credit agreement also provides for a five-year $1,000 senior secured revolving credit facility (the Revolving Credit Facility). The proceeds of any loans made under the Revolving Credit Facility can be used for capital expenditures, acquisitions, working capital needs and other general corporate purposes. We had no borrowings outstanding under our Revolving Credit Facility at September 30, 2015, and we had $129 in letters of credit issued and outstanding under this facility. The Revolving Credit Facility bears variable interest of a range based on our total net leverage ratio between (a) 0.50% and 1.25% for base rate loans and (b) 1.50% and 2.25% for LIBOR loans. The applicable margin was 1.00% for base rate loans and 2.00% for LIBOR loans as of September 30, 2015. In addition, we are required to pay a commitment fee on the average daily unused amount of the Revolving Credit Facility at a rate based on our total net leverage ratio, between 0.20% and 0.35%. Commitment fees are currently assessed at a rate of 0.30%.

The credit agreement contains financial covenants which, solely with respect to the Revolving Credit Facility, require Chemours (i) not to exceed a maximum total net leverage ratio and, (ii) unless Chemours has achieved an investment grade rating (as specified in the credit agreement), to maintain a minimum interest coverage ratio of greater than or equal to 3.00 to 1.00. In addition, the credit agreement contains customary affirmative and negative covenants that, among other things, limit or restrict Chemours and its subsidiaries' ability, subject to certain exceptions, to incur liens, merge, consolidate or sell, transfer or lease assets, make investments, pay dividends, transact with subsidiaries and incur indebtedness. The credit agreement also contains customary representations and warranties and events of default.

During the third quarter of 2015, Chemours and its Revolving Credit Facility lenders agreed to amend certain provisions of the credit agreement that relate to the Revolving Credit Facility, strengthening Chemours' financial position by providing enhanced liquidity to implement the Transformation Plan. The amendment modified the consolidated EBITDA definition in the covenant calculation to include pro forma benefits of announced cost reduction initiatives.

Chemours’ obligations under the senior secured credit facilities are guaranteed on a senior secured basis by all of its material domestic subsidiaries, subject to certain agreed upon exceptions. The obligations under the senior secured credit facilities are also, subject to certain agreed upon exceptions, secured by a first priority lien on substantially all of Chemours and its material wholly-owned domestic subsidiaries’ assets, including 100% of the stock of domestic subsidiaries and 65% of the stock of certain foreign subsidiaries.

Senior Unsecured Notes

On May 12, 2015, Chemours issued senior unsecured notes (the Notes) with an aggregate principal of approximately $2,503 in a private placement subject to a registration rights arrangement.

All of the notes, including the 2023 notes with an aggregate principal amount of $1,350, the 2025 notes with an aggregate principal amount of $750 and the 2023 Euro notes with an aggregate principal amount of €360 ($403), require payment of principal at maturity and interest semi-annually in cash in arrears on May 15 and November 15 of each year.

The proceeds from the Notes were used to fund the cash and in-kind distributions to DuPont and to pay related fees and expenses. The in-kind distribution to DuPont of $507 aggregate principal amount of Chemours 2025 Notes were exchanged by DuPont with third parties for certain DuPont notes.

Chemours is required to register the Notes with the SEC within 465 days after the original issue date. If Chemours fails to do so, it would be required to pay additional interest at a rate of 0.25% for the first 90 days following a registration default and additional 0.25% per annum with respect to each subsequent 90-day period, up to a maximum rate of 0.50%, until the registration requirements are met. Application is also expected to be made to the Irish Stock Exchange for the approval of listing particulars in relation to the Euro notes prior to the first anniversary of the issue date of the Euro notes.

Maturities

There are no debt maturities in each of the next seven years, except, in accordance with the credit agreement, Chemours has required quarterly principal payments related to the Term Loan Facility equivalent to 1.00% per annum beginning September 2015 through March 2022, with the balance due at maturity. Term Loan principal maturities over the next five years are $4 during the fourth quarter of 2015 and $15 in each year from 2016 to 2021. Debt maturities related to the Term Loan Facility and the Notes in 2021 and beyond will be $3,920.

Debt Fair Value

The fair values of the Term Loan Facility, the 2023 notes, the 2025 notes and the 2023 Euro notes at September 30, 2015 were approximately $1,362, $906, $494 and $268, respectively. The estimated fair values of the Term Loan Facility and the Notes are based on quotes received from third party brokers, and are classified as Level 2 in the fair value hierarchy.

Commitments and Contingent Liabilities	9 Months Ended
Commitments and Contingent Liabilities	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingent Liabilities	Commitments and Contingent Liabilities (a) Guarantees Chemours has directly guaranteed various obligations of customers, suppliers and other third parties. At September 30, 2015 and December 31, 2014, Chemours had directly guaranteed $9 and $41 of such obligations, respectively. These represent the maximum potential amount of future (undiscounted) payments that Chemours could be required to make under the guarantees in the event of default by the guaranteed parties. No amounts were accrued at September 30, 2015 and December 31, 2014. Chemours assesses the payment and performance risk by assigning default rates based on the duration of the guarantees. These default rates are assigned based on the external credit rating of the counterparty or through internal credit analysis and historical default history for counterparties that do not have published credit ratings. For counterparties without an external rating or available credit history, a cumulative average default rate is used. (b) Litigation In addition to the matters discussed below, Chemours, by virtue of its status as a subsidiary of DuPont prior to the Distribution, is subject to various pending legal proceedings arising out of the normal course of the Chemours business including product liability, intellectual property, commercial, environmental and antitrust lawsuits. It is not possible to predict the outcome of these various proceedings. Except for the PFOA litigation for which a separate assessment is provided in this Note, while management believes it is reasonably possible that Chemours could incur losses in excess of the amounts accrued, if any, for the aforementioned proceedings, it does not believe any such loss would have a material impact on Chemours' consolidated financial position, results of operations or liquidity. With respect to the litigation matters discussed below, management's estimate of the probability of loss in excess of the amounts accrued, if any, is addressed individually for each matter. Asbestos At September 30, 2015, there were approximately 2,360 lawsuits pending against DuPont alleging personal injury from exposure to asbestos. These cases are pending in state and federal court in numerous jurisdictions in the U.S. and are individually set for trial. Most of the actions were brought by contractors who worked at sites between 1950 and the 1990s. A small number of cases involve similar allegations by DuPont employees. A limited number of the cases were brought by household members of contractors or DuPont employees. Finally, certain lawsuits allege personal injury as a result of exposure to DuPont products. At September 30, 2015 and December 31, 2014, Chemours had an accrual of $38 related to this matter. Additionally, Chemours had an accrual for $2 for asbestos cases outside the U.S. at September 30, 2015. Management believes that the likelihood is remote that Chemours would incur losses in excess of the amounts accrued in connection with this matter. Benzene In the separation, DuPont assigned its Benzene docket to Chemours. There are 28 pending cases against DuPont alleging benzene-related illnesses. These cases consist of premises matters involving contractors and deceased former employees who claim exposure to benzene while working at DuPont sites primarily in the 1960s through the 1980s, and product liability claims based on alleged exposure to benzene found in trace amounts in aromatic hydrocarbon solvents used to manufacture DuPont products, such as paints, thinners and reducers. A benzene case (Hood v. DuPont) was tried to a verdict in Texas state court on October 20, 2015. Plaintiffs alleged that Mr. Hood's Acute Myelogenous Leukemia (AML) was the result of 24 years of occupational exposure to trace benzene found in DuPont automotive paint products and that DuPont negligently failed to warn him that its paints, reducers and thinners contained benzene that could cause cancer or leukemia. The jury found in the Plaintiffs favor awarding $6.9 in compensatory damages and $1.5 in punitive damages. Through DuPont, Chemours will appeal the verdict based upon substantial errors made at the trial court. Management believes that a loss is reasonably possible related to these matters; however, given the evaluation of each Benzene matter is highly fact driven and impacted by disease, exposure and other factors, a range of such losses cannot be reasonably estimated at this time. PFOA Prior to the fourth quarter of 2014, Chemours used PFOA (collectively, perfluorooctanoic acids and its salts, including the ammonium salt) as a processing aid to manufacture some fluoropolymer resins at various sites around the world including its Washington Works plant in West Virginia. Chemours had accruals of $14 related to the PFOA matters discussed below at September 30, 2015 and December 31, 2014. The accruals include charges related to DuPont’s obligations under agreements with the U.S. Environmental Protection Agency (EPA) and voluntary commitments to the New Jersey Department of Environmental Protection. These obligations and voluntary commitments include surveying, sampling and testing drinking water in and around certain company sites and offering treatment or an alternative supply of drinking water if tests indicate the presence of PFOA in drinking water at or greater than the national Provisional Health Advisory. Drinking Water Actions In August 2001, a class action, captioned Leach v. DuPont, was filed in West Virginia state court alleging that residents living near the Washington Works facility had suffered, or may suffer, deleterious health effects from exposure to PFOA in drinking water. DuPont and attorneys for the class reached a settlement in 2004 that binds about 80,000 residents. In 2005, DuPont paid the plaintiffs’ attorneys’ fees and expenses of $23 and made a payment of $70, which class counsel designated to fund a community health project. Chemours, through DuPont, funded a series of health studies which were completed in October 2012 by an independent science panel of experts (the C8 Science Panel). The studies were conducted in communities exposed to PFOA to evaluate available scientific evidence on whether any probable link exists, as defined in the settlement agreement, between exposure to PFOA and human disease. The C8 Science Panel found probable links, as defined in the settlement agreement, between exposure to PFOA and pregnancy-induced hypertension, including preeclampsia, kidney cancer, testicular cancer, thyroid disease, ulcerative colitis and diagnosed high cholesterol. In May 2013, a panel of three independent medical doctors released its initial recommendations for screening and diagnostic testing of eligible class members. In September 2014, the medical panel recommended follow-up screening and diagnostic testing three years after initial testing, based on individual results. The medical panel has not communicated its anticipated schedule for completion of its protocol. Through DuPont, Chemours is obligated to fund up to $235 for a medical monitoring program for eligible class members and, in addition, administrative cost associated with the program, including class counsel fees. In January 2012, Chemours, through DuPont, put $1 in an escrow account to fund medical monitoring as required by the settlement agreement. The court-appointed Director of Medical Monitoring has established the program to implement the medical panel’s recommendations and the registration process, as well as eligibility screening, is ongoing. Diagnostic screening and testing has begun and associated payments to service providers are being disbursed from the escrow account. As of September 30, 2015, less than $1 has been disbursed from the escrow account related to medical monitoring. In addition, under the settlement agreement, DuPont must continue to provide water treatment designed to reduce the level of PFOA in water to six area water districts, including the Little Hocking Water Association (LHWA) and private well users. Class members may pursue personal injury claims against DuPont only for those human diseases for which the C8 Science Panel determined a probable link exists. At September 30, 2015, there were approximately 3,500 lawsuits filed in various federal and state courts in Ohio and West Virginia. These lawsuits are consolidated in multi-district litigation in Ohio federal court (MDL). Based on the information currently available to the company, the majority of the lawsuits allege personal injury claims associated with high cholesterol and thyroid disease from exposure to PFOA in drinking water. There are 37 lawsuits alleging wrongful death. In the third quarter of 2014, six plaintiffs from the MDL were selected for individual trial. The first case (Bartlett v. DuPont) was tried to a verdict on October 7, 2015. The Plaintiff alleged that PFOA in drinking water caused her kidney cancer with causes of action for negligence and negligent infliction of emotional distress. Ohio law applied to the causes of action and damages. The jury found in favor of the Plaintiff awarding $1.1 in damages for negligence and $0.5 for emotional distress. The jury found that DuPont’s conduct did not warrant punitive damages. Chemours, through DuPont, will appeal the verdict based upon substantial errors made at the trial court. The second case (Wolf v. DuPont) is set for trial in March 2016. This case involves a Plaintiff alleging damages for ulcerative colitis. West Virginia law will apply to the causes of action and damages. Chemours, through DuPont, denies the allegations in these lawsuits and is defending itself vigorously. No claims have been settled or resolved during the periods presented. Additional Actions An Ohio action brought by the LHWA against DuPont is ongoing. In addition to general claims of PFOA contamination of drinking water, the action claims “imminent and substantial endangerment to health and or the environment” under the Resource Conservation and Recovery Act (RCRA). In the second quarter of 2014, DuPont filed a motion for summary judgment. The LHWA moved for partial summary judgment. During the second quarter, the court granted in part and denied in part both parties' motions for summary judgment. A settlement conference is scheduled for November 2015 and a trial is set for January 2016. Chemours, through DuPont, denies these claims and is defending itself vigorously. Ohio law will apply to the causes of action and damages. PFOA Summary While it is probable that the company will incur costs related to the medical monitoring program discussed above, such costs cannot be reasonably estimated due to uncertainties surrounding the level of participation by eligible class members and the scope of testing. Chemours believes that it is reasonably possible that it could incur losses related to the LHWA and MDL in Ohio federal court discussed above but such losses cannot be estimated at this time. In the MDL in Ohio federal court, a range of such losses cannot be reasonably estimated at this time due to the uniqueness of the individual MDL plaintiff's claims and Chemours' defenses to those claims, both as to potential liability and damages on an individual claim basis, among other factors. The trials and appeals of these matters will occur over the course of many years. Significant unfavorable outcomes in a number of cases in the MDL could have a material adverse effect on Chemours' consolidated financial position, results of operations or liquidity. (c) Environmental Chemours, by virtue of its status as a subsidiary of DuPont prior to the Distribution, is subject to contingencies pursuant to environmental laws and regulations that in the future may require further action to correct the effects on the environment of prior disposal practices or releases of chemical substances by Chemours or other parties. Chemours accrues for environmental remediation activities consistent with the policy set forth in Note 3 to the Annual Combined Financial Statements in our Information Statement included in our Registration Statement. Much of this liability results from the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA, often referred to as Superfund), RCRA and similar state and global laws. These laws require Chemours to undertake certain investigative, remediation and restoration activities at sites where Chemours conducts or once conducted operations or at sites where Chemours-generated waste was disposed. The accrual also includes estimated costs related to a number of sites identified for which it is probable that environmental remediation will be required, but which are not currently the subject of enforcement activities. Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, diverse regulatory agencies and enforcement policies, as well as the presence or absence of other potentially responsible parties. At September 30, 2015, the Interim Consolidated Balance Sheets included a liability of $300, relating to these matters which, in management’s opinion, is appropriate based on existing facts and circumstances. The average time frame, over which the accrued or presently unrecognized amounts may be paid, based on past history, is estimated to be 15 to 20 years. Therefore, considerable uncertainty exists with respect to environmental remediation costs and, under adverse changes in circumstances, the potential liability may range up to approximately $630 above the amount accrued at September 30, 2015. Except for Pompton Lakes, which is discussed further below, based on existing facts and circumstances, management does not believe that any loss, in excess of amounts accrued, related to remediation activities at any individual site will have a material impact on the financial position, liquidity or results of operations of Chemours. Pompton Lakes The environmental remediation accrual at September 30, 2015 includes $88 related to activities at Chemours’ site in Pompton Lakes, New Jersey. Management believes that it is reasonably possible that potential liability for remediation activities at this site could range up to $119 including previously accrued amounts. This could have a material impact on the liquidity of Chemours in the period recognized. During the twentieth century, blasting caps, fuses and related materials were manufactured at Pompton Lakes. Operating activities at the site were ceased in the mid 1990s. Primary contaminants in the soil and sediments are lead and mercury. Ground water contaminants include volatile organic compounds. Under the authority of the EPA and the New Jersey Department of Environmental Protection, remedial actions at the site are focused on investigating and cleaning up the area. Ground water monitoring at the site is ongoing and Chemours has installed and continues to install vapor mitigation systems at residences within the ground water plume. In addition, Chemours is further assessing ground water conditions. In June 2015, the EPA issued a modification to the site's RCRA permit that requires Chemours to dredge mercury contamination from a 36 acre area of the lake and remove sediment from two other areas of the lake near the shoreline. Chemours expects to spend about $50 over the next two to three years in connection with remediation activities commencing in mid-2016 at Pompton Lakes, including activities related to the EPA’s proposed plan. These amounts are included in the remediation accrual at September 30, 2015.

Financial Instruments

9 Months Ended

Sep. 30, 2015

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Financial Instruments

Derivative Instruments

Objectives and Strategies for Holding Derivative Instruments

In the ordinary course of business, Chemours enters into contractual arrangements (derivatives) to reduce its exposure to foreign currency risks. The Company has established a derivative program to be utilized for financial risk management. This program reflects varying levels of exposure coverage and time horizons based on an assessment of risk. The derivative program has procedures consistent with Chemours’ financial risk management policies and guidelines.

Foreign Currency Forward Contracts

Chemours uses foreign currency forward contracts to reduce its net exposure, by currency, related to non-functional currency-denominated monetary assets and liabilities of its operations so that exchange gains and losses resulting from exchange rate changes are minimized. These derivative instruments are not part of a cash flow hedge program or a fair value hedge program, and have not been designated as a hedge. Although all of the forward contracts are subject to an enforceable master netting agreement, Chemours has elected to present the derivative assets and liabilities on a gross basis in the Interim Consolidated Balance Sheets. No collateral has been required for these contracts. All gains and losses resulting from the revaluation of the derivative assets and liabilities are recognized in other income, net in the Interim Consolidated Statements of Operations during the period in which they occurred.

At September 30, 2015, there were 64 forward exchange currency contracts outstanding with an aggregate gross notional value of $1,030. Chemours recognized a gain of $66 and $78 for the three and nine month periods ended September 30, 2015, respectively in other income, net in the Interim Consolidated Statements of Operations. There were no forward contracts outstanding in 2014.

Net Investment Hedge - Foreign Currency Borrowings

On July 1, 2015, Chemours designated its €360 million Euro notes (see Note 15) as a hedge of its net investments in certain of its international subsidiaries that use the Euro as functional currency in order to reduce the volatility in stockholders’ equity caused by the changes in foreign currency exchange rates of the Euro with respect to the U.S. Dollar. Chemours used the spot method to measure the effectiveness of the net investment hedge. Under this method, for each reporting period, the change in the carrying value of the Euro notes due to remeasurement of the effective portion is reported in accumulated other comprehensive loss in the Interim Consolidated Balance Sheet and the remaining change in the carrying value of the ineffective portion, if any, is recognized in other income, net in the Interim Consolidated Statements of Operations. Chemours evaluates the effectiveness of its net investment hedge quarterly. For the three and nine months ended September 30, 2015, Chemours did not record any ineffectiveness and recognized gains of less than $1 on its net investment hedges within cumulative translation adjustment in AOCI. There were no net investment hedges in 2014.

Fair Value of Derivative Instruments

The table below presents the fair value of Chemours’ derivative assets and liabilities within the fair value hierarchy, as described in Note 3 to the Interim Consolidated Financial Statements.



		Fair Value Using Level 2 Inputs
	Balance Sheet Location	September 30, 2015		December 31, 2014
Asset derivatives:
Foreign currency forward contracts	Accounts and notes receivable - trade, net	$	9	$	—
Total asset derivatives		$	9	$	—

Liability derivatives
Foreign currency forward contracts	Other accrued liabilities	$	3	$	—
Total liability derivatives		$	3	$	—

We classify our foreign currency forward contracts in Level 2 as the valuation inputs are based on quoted prices and market observable data of similar instruments. For derivative assets and liabilities, standard industry models are used to calculate the fair value of the various financial instruments based on significant observable market inputs, such as foreign exchange rates and implied volatilities obtained from various market sources. Market inputs are obtained from well-established and recognized vendors of market data and subjected to tolerance/quality checks.

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5580258-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624181-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41638-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Long-Term Employee Benefits

9 Months Ended

Sep. 30, 2015

General Discussion of Pension and Other Postretirement Benefits [Abstract]

Long-Term Employee Benefits

Plans Covering Employees in the U.S.

On July 1, 2015, in connection with the separation from DuPont, Chemours employees stopped participating in various DuPont plans, including the DuPont Pension and Retirement Plan in the U.S. and certain other long-term employee benefits. DuPont retained all liabilities related to its U.S. plans post-separation.

Chemours sponsors a defined contribution plan, which covers all U.S. employees. The plan is a tax-qualified contributory profit sharing plan, with cash or deferred arrangement, and any eligible employee of Chemours may participate. Chemours contributes 100% of the first 6% of the employee’s contribution election and also contributes 3% of each eligible employee’s eligible compensation regardless of the employee’s contribution. The plan's matching contributions vest immediately upon contribution. The 3% non-matching contribution vests for employees with at least three years of service. Enhanced 401(k) benefits are also provided to former participants of the DuPont pension plan.

Plans Covering Employees Outside the U.S.

Pension coverage for employees of Chemours non-U.S. subsidiaries is provided, to the extent deemed appropriate, through separate plans established after separation and comparable to the DuPont plans in those countries. Obligations under such plans are funded by depositing funds with trustees, covered by insurance contracts or remain unfunded.

Participation in the Plans

Prior to July 1, 2015, Chemours participated in DuPont’s U.S. and non-U.S. plans as though they were participants in a multi-employer plan with the other businesses of DuPont. More information on the financial status of DuPont’s significant plans can be found in DuPont’s Annual Report on Form 10-K. The following table presents the expense for DuPont’s significant plans in which Chemours participated prior to separation and are accounted for as multi-employer plans.



		Three months ended September 30,					Nine months ended September 30,
Plan Name	EIN / Pension Number	2015		2014			2015		2014
DuPont Pension and Retirement Plan (U.S.)	51-0014090/001	$	—	$	13		$	48	$	38
All other U.S. and non-U.S. Plans		—		(1		)	5		2

The above table does not include pension plans covering Chemours' employees in various non-U.S. plans. See below for further discussion of these plans. For purposes of these financial statements, the amounts in the tables above represent the allocation of cost to Chemours included in the income statements of Chemours, which was allocated based on active employee headcount. These figures do not represent cash payments to DuPont, or DuPont’s plans.

Single and Multiple Employer Plans

Beginning in the first quarter of 2015, Chemours has accounted for the plans covering its employees in the Netherlands and Taiwan as a multiple employer plan and a single employer plan, respectively. In the third quarter of 2015, in connection with the separation, additional plans in Germany, Belgium, Japan, Korea, Mexico and Switzerland were established. As of September 30, 2015, these plans were all accounted for as single employer plans. The pre-tax amounts recognized in accumulated other comprehensive (loss) income are summarized below:



Pension Benefits	September 30, 2015
Net loss	$	362
Prior service cost	(8		)
Total amount recognized in accumulated other comprehensive (loss) income	$	354

At January 1, 2015, the accumulated benefit obligation and projected benefit obligation for the non-U.S. plans were $1,186 and $1,309, respectively. The fair value of assets in the non-U.S. plans, net of plan liabilities was $1,288, which includes a contribution of $28 to the Taiwan plan in 2015 made by DuPont, on behalf of Chemours. Valuations for the single and multiple employer plans covering Chemours' employees were obtained as of January 1, 2015 and the information presented is in accordance with the valuation of these plans as of that date.



Pension Benefits	Three Months Ended September 30, 2015			Nine Months Ended September 30, 2015
Components of net periodic pension cost:
Net periodic benefit (credit) cost:
Service cost	$	5		$	11
Interest cost	5			14
Expected return on plan assets	(21		)	(61		)
Amortization of loss	1			8
Amortization of prior service cost	4			6
Net periodic benefit (credit) cost	$	(6	)	$	(22	)

The estimated pre-tax net loss and prior service cost for the defined benefit pension plans that will be amortized from accumulated other comprehensive (loss) income into net periodic benefit cost during the remainder of 2015 is $5.

Assumptions

For the non-U.S. plans, the Company utilizes prevailing long-term high quality corporate bond indices to determine the discount rate applicable to each country at the measurement date. For these plans, the long term rate of return on assets reflects economic assumptions applicable to each country.

The following assumptions have been used to determine the benefit obligations and net benefit cost:



Weighted average assumptions used to determine benefit obligations as of January 1, 2015 and benefit cost for the nine months ended September 30, 2015	Pension Benefit Obligations at January 1, 2015		Benefits Cost for the nine months ended September 30, 2015
Discount rate	2	%	3	%
Expected return on plan assets	7	%	7	%
Rate of compensation increase ¹	4	%	4	%

¹ The rate of compensation increase represents the single annual effective salary increase that an average plan participant would receive during the participant's entire career at Chemours.

Plan Assets

The non-U.S. plan assets are maintained by Chemours. Each pension plan's assets are invested through a master trust fund. The strategic asset allocation for this trust fund is selected by management, reflecting the results of comprehensive asset and liability modeling. Chemours establishes strategic asset allocation percentage targets and appropriate benchmarks for significant asset classes with the aim of achieving a prudent balance between return and risk. Strategic asset allocations in countries are selected in accordance with the laws and practices of those countries.

The weighted average target allocation for Chemours' pension plan assets is summarized as follows:



	January 1, 2015
U.S. equity securities	25	%
Non-U.S.equity securities	25	%
Fixed income securities	50	%
Total	100	%

Fixed income securities include corporate issued, government issued and asset backed securities. Corporate debt investments include a range of credit risk and industry diversification. U.S. fixed income investments are weighted more heavily than non-U.S. fixed income securities.

Fair value calculations may not be indicative of net realizable value or reflective of future fair values. Furthermore, although Chemours believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

The table below presents the fair values of Chemours' pension assets by level within the fair value hierarchy, as described in Note 3 of the Interim Consolidated Financial Statements, as of January 1, 2015.



	Total			Level 1		Level 2
Asset Category:
Debt - government issued	$	553		$	24	$	529
Debt - corporate issued	150			52		98
Debt - asset backed	38			3		35
U.S. and non U.S. equities	538			52		486
Derivatives - asset position	33			—		33
Derivatives - liability position	(12		)	—		(12		)
Other	5			2		3
	1,305			$	133	$	1,172
Pension trust payables ¹	(17		)
Total	$	1,288

¹Primarily payables for investment securities purchased.

For pension plan assets classified as Level 1, total fair value is either the price of the most recent trade at the time of the market close or the official close price, as defined by the exchange on which the asset is most actively traded on the last trading day of the period, multiplied by the number of units held without consideration of transaction costs.

For pension or other postretirement benefit plan assets classified as Level 2, where the security is frequently traded in less active markets, fair value is based on the closing price at the end of the period; where the security is less frequently traded, fair value is based on the price a dealer would pay for the security or similar securities, adjusted for any terms specific to that asset or liability. Market inputs are obtained from well-established and recognized vendors of market data and subjected to tolerance and quality checks. For derivative assets and liabilities, standard industry models are used to calculate the fair value of the various financial instruments based on significant observable market inputs, such as foreign exchange rates, commodity prices, swap rates, interest rates and implied volatilities obtained from various market sources.

Cash Flow

Defined Benefit Plan

DuPont contributed, on behalf of Chemours, $35 to its pension plans other than the principal U.S. pension plan in 2014. DuPont contributed, on behalf of Chemours, $66 to its other long-term employee benefit plans in 2014. DuPont contributed $38 in the first half of 2015 and Chemours contributed $4 in the third quarter of 2015. Chemours expects to contribute an additional $4 to its pension plans, and expects contributions to its other long-term employee benefit plans to be approximately the same as contributions in 2014.

Estimated future benefit payments

The following benefit payments, which are related to non-U.S. plans that are predominantly Chemours and reflect future service, as appropriate, are expected to be paid:



Year ended December 31,	Benefits
Remainder of 2015	$	10
2016	44
2017	48
2018	47
2019	49
2020-2024	265

Segment Information

9 Months Ended

Sep. 30, 2015

Segment Reporting [Abstract]

Segment Information

Chemours’ operations are classified into three reportable segments based on similar economic characteristics, the nature of products and production processes, end-use markets, channels of distribution and regulatory environment. Chemours’ reportable segments are Titanium Technologies, Fluoroproducts and Chemical Solutions. Corporate costs and certain legal and environmental expenses that are not aligned with the reportable segments and foreign exchange gains and losses are reflected in Corporate and Other. Prior to September 30, 2015, foreign exchange gains and losses were reflected in the three reportable segments.

Segment sales include transfers to another reportable segment. Adjusted EBITDA is the primary measure of segment profitability used by the Chief Operating Decision Maker (CODM) and is defined as income (loss) before income taxes excluding the following:


•	interest expense, depreciation and amortization,


•	non-operating pension and other postretirement employee benefit costs,


•	exchange gains (losses),


•	employee separation, asset-related charges and other charges, net,


•	asset impairments,


•	gains (losses) on sale of business or assets, and


•	other items not considered indicative of our ongoing operational performance and expected to occur infrequently.

The tables presented below reflect the reclassification of certain corporate costs, certain legal and environmental expenses that are not aligned with our reportable segments, and foreign exchange gains and losses from our reportable segments into Corporate and Other. All periods presented reflect the current definition of Adjusted EBITDA.



Three months ended September 30,	Titanium Technologies		Fluoroproducts		Chemical Solutions		Corporate and Other			Total
2015
Sales	$	616	$	576	$	295	$	—		$	1,487
Less: Transfers	—		1		—		—			1
Net sales	$	616	$	575	$	295	$	—		$	1,486
Adjusted EBITDA	78		89		7		(5		)	$	169
Depreciation and amortization	32		23		14		1			70

2014
Sales	$	755	$	572	$	306	$	—		$	1,633
Less: Transfers	1		—		—		—			1
Net sales	$	754	$	572	$	306	$	—		$	1,632
Adjusted EBITDA	189		70		9		(33		)	235
Depreciation and amortization	29		16		12		—			57



Nine months ended September 30,	Titanium Technologies		Fluoroproducts		Chemical Solutions		Corporate and Other			Total
2015
Sales	$	1,804	$	1,716	$	839	$	—		$	4,359
Less: Transfers	1		1		—		—			2
Net sales	$	1,803	$	1,715	$	839	$	—		$	4,357
Adjusted EBITDA	262		218		12		(51		)	441
Depreciation and amortization	95		65		40		1			201

2014
Sales	$	2,254	$	1,752	$	882	$	—		$	4,888
Less: Transfers	5		—		—		—			5
Net sales	$	2,249	$	1,752	$	882	$	—		$	4,883
Adjusted EBITDA	563		209		16		(117		)	671
Depreciation and amortization	90		59		36		—			185

Total Adjusted EBITDA reconciles to total consolidated income before income taxes on the Interim Consolidated Statements of Operations as follows:

Reconciliation to Consolidated Statements of Operations



	Three months ended September 30,						Nine months ended September 30,
	2015			2014			2015			2014
Total Adjusted EBITDA	$	169		$	235		$	441		$	671
Interest	(51		)	—			(79		)	—
Depreciation and amortization	(70		)	(57		)	(201		)	(185		)
Non-operating pension and other postretirement employee benefit costs	10			(3		)	(5		)	(18		)
Exchange gains (losses)	44			(33		)	47			(29		)
Asset impairments	(70		)	—			(70		)	—
Restructuring charges	(139		)	—			(200		)	(21		)
Gains (losses) on sale of business or assets	—			1			—			12
(Loss) income before income taxes	(107		)	143			(67		)	430
(Benefit from) provision for income taxes	(78		)	35			(63		)	108
Net (loss) income	$	(29	)	$	108		$	(4	)	$	322

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

+ Details

Stock-based Compensation

9 Months Ended

Sep. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-based Compensation

Stock-based Compensation

Total stock-based compensation cost included in the Consolidated Statements of Operations was $8 and $13 for the three and nine months ended September 30, 2015, respectively, and $2 and $6 for the three and nine months ended September 30, 2014, respectively. The income tax benefits related to stock-based compensation arrangements were $3 and $5 for the three and nine months ended September 30, 2015, respectively and less than $1 and $2 for the three and nine months ended September 30, 2014, respectively.

Stock-based compensation expense in 2014 and until separation on July 1, 2015 was allocated to Chemours based on the portion of DuPont’s incentive stock program in which Chemours employees participated. Adopted at separation, The Chemours Company Equity and Incentive Plan grants certain employees, independent contractors, or non-employee directors of the Company different forms of benefits, including stock options and restricted stock units (RSUs).

In accordance with the Employee Matters Agreement between DuPont and Chemours, certain executives and employees were entitled to receive equity compensation awards of Chemours in replacement of previously outstanding awards granted under various DuPont stock incentive plans prior to the separation. In connection with the spin-off, these awards were converted into new Chemours equity awards using a formula designed to preserve the intrinsic value of the awards immediately prior to the July 1, 2015 spin-off. As a result of the conversion of these awards, we recorded an approximate $3 incremental charge in the third quarter of 2015. The terms and conditions of the DuPont awards were replicated and as necessary, adjusted to ensure that the vesting schedule and economic value of the awards was unchanged by the conversion.

Stock Options

Chemours granted non-qualified options to employees in July 2015 representing replacement of previously granted performance stock unit awards at DuPont. Other than those options, Chemours' expense related to stock options was entirely related to options granted to replace outstanding option awards from DuPont that were converted to Chemours options on July 1, 2015.

The expense related to stock options granted in the three and nine months ended September 30, 2015 was based on the assumptions shown in the table below.



Assumptions used to calculate expense for stock options	For the three and nine months ended September 30, 2015
Assumptions used to calculate expense for stock options	For the three and nine months ended September 30, 2015
Risk-free interest rate	1.5		%
Average life of options (years)	5.4
Volatility	42.0		%
Dividend yield	6.9		%
Fair value per stock option	$	3.17

The following table summarizes Chemours stock option activity for the three months ended September 30, 2015.



	Number of Shares (in thousands)		Weighted Average Exercise Price(per share)	Weighted Average Remaining Contractual Term (years)	Aggregate Intrinsic Value (in thousands)
Outstanding, June 30, 2015	—		N/A
Converted on July 1, 2015	7,793		14.56
Granted	662		16.04
Exercised	—		N/A
Forfeited	(107	)	17.16
Canceled	—		N/A
Outstanding, September 30, 2015	8.348		14.65	5.06	243
Exercisable, September 30, 2015	5,286		13.72	4.19	243

The aggregate intrinsic values in the table above represent the total pre-tax intrinsic value (the difference between the company's closing stock price on the last trading day of September 30, 2015 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their in-the-money options at quarter end. The amount changes based on the fair market value of the company's stock. No options were exercised in the three months ended September 30, 2015.

As of September 30, 2015, $5 of total unrecognized compensation cost related to stock options is expected to be recognized over a weighted-average period of 2.11 years.

RSUs

The company issues RSUs that serially vest over a three-year period and, upon vesting, convert one-for-one to Chemours common stock. A retirement eligible employee retains any granted awards upon retirement provided the employee has rendered at least six months of service following the grant date. Additional RSUs are also granted periodically to key senior management employees with a performance condition. These RSUs generally vest over periods ranging from two to five years. The fair value of all stock-settled RSUs is based upon the market price of the underlying common stock as of the grant date.

Non-vested awards of RSUs, both with and without performance feature, as of September 30, 2015 are shown below. The weighted-average grant-date fair value of RSUs granted during 2015 was $14.94.



	Number of Shares (in thousands)		Weighted Average Grant Date Fair Value (per share)
Nonvested, June 30, 2015	—		—
Converted, July 1, 2015	1,438		16.00
Granted	1,065		13.50
Vested	(11	)	16.00
Forfeited	(13	)	16.00
Nonvested, September 30, 2015	2,479		14.94

As of September 30, 2015, there was $28 of unrecognized stock-based compensation expense related to nonvested awards. That cost is expected to be recognized over a weighted-average period of 2.22 years.

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Foreign Currency Translation	Foreign Currency Translation Chemours identifies its separate and distinct foreign entities and groups them into two categories: 1) extension of the parent (U.S. dollar functional currency) and 2) self-contained (local functional currency). If a foreign entity does not align with either category, factors are evaluated and a judgment is made to determine the functional currency. Chemours changes the functional currency of its separate and distinct foreign entities only when significant changes in economic facts and circumstances indicate clearly that the functional currency has changed. During the periods covered by the Interim Consolidated Financial Statements, part of the Chemours business operated within foreign entities. For foreign entities where the U.S. dollar is the functional currency, all foreign currency-denominated asset and liability amounts are remeasured into U.S. dollars at end-of-period exchange rates, except for inventories, prepaid expenses, property, plant and equipment, goodwill and other intangible assets, which are remeasured at historical rates. Foreign currency-denominated income and expenses are remeasured at average exchange rates in effect during the period, except for expenses related to balance sheet amounts remeasured at historical exchange rates. Exchange gains and losses arising from remeasurement of foreign currency-denominated monetary assets and liabilities are included in other income, net in the period in which they occur. For foreign entities where the local currency is the functional currency, assets and liabilities denominated in local currencies are translated into U.S. dollar at end-of-period exchange rates and the resulting translation adjustments are reported as a component of accumulated other comprehensive (loss) income in equity. Assets and liabilities denominated in other than the functional currency are remeasured into the functional currency prior to translation into U.S. dollars and the resulting exchange gains or losses are included in income in the period in which they occur. Income and expenses are translated into U.S. dollars at average exchange rates in effect during the period. Beginning in 2015, when the Chemours operations were legally and operationally separated within DuPont in anticipation of the spin-off, some of the resulting newly created Chemours foreign entities set their local currency as the functional currency.
Employee Benefits	Employee Benefits Prior to separation, certain of Chemours’ employees participated in defined benefit pension and other post-employment benefit plans (the Plans) sponsored by DuPont and accounted for by DuPont in accordance with accounting guidance for defined benefit pension and other post-employment benefit plans. Substantially all expenses related to these plans were allocated in shared entities and reported within costs of goods sold, selling, general and administrative expenses and research and development expense in the Interim Consolidated Statements of Operations. Chemours considered all plans to be part of a multi-employer plan with DuPont prior to January 1, 2015. In connection with the spin-off, Chemours retained the existing Netherlands pension plan and an agreement was executed in 2015 to ensure continuance of the plan for both DuPont and Chemours employees and retirees. As a result of that agreement, Chemours now accounts for the Netherlands plan as a multiple employer plan. Additionally, in 2015, Chemours formed new pension plans in Taiwan, Germany, Belgium, Switzerland, Japan, Korea and Mexico that mirror the plans historically operated by DuPont in these countries. The new plans are accounted for under the single employer method. See Note 18 for additional information.
Derivatives	Derivatives Prior to 2015, Chemours participated in DuPont’s foreign currency hedging program to reduce earnings and cash flow volatility associated with foreign currency exchange rate changes. DuPont formally documented the hedge relationships, including identification of the hedging instruments and the hedged items, the risk management objectives and strategies for undertaking the hedge transactions and the methodologies used to assess effectiveness and measure ineffectiveness. Realized gains and losses on derivative instruments of DuPont were allocated by DuPont to Chemours based on projected exposure. Chemours recognized its allocable share of the gains and losses on DuPont’s derivative financial instruments in earnings when the forecasted sales occurred for foreign currency hedges. The foreign currency hedges qualified as cash flow hedges, and the realized gains recognized in earnings were less than $1 for the three and nine months ended months ended September 30, 2014. Chemours’ participation in this program terminated as of January 1, 2015. Beginning in February 2015, Chemours began entering into forward currency exchange contracts to minimize volatility in earnings related to the foreign exchange gains and losses resulting from remeasuring net monetary assets that Chemours holds which are denominated in non-functional currencies. Chemours does not hold or issue financial instruments for speculative or trading purposes. The derivative assets and liabilities are reported on a gross basis in the Interim Consolidated Balance Sheets. All gains and losses resulting from the revaluation of the derivative assets and liabilities are recognized in other income, net in the Interim Consolidated Statements of Operations during the period in which they occurred.
Fair Value Measurement	Fair Value Measurement Under the accounting for fair value measurements and disclosures, a fair value hierarchy was established that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical asset and liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Chemours uses the following valuation techniques to measure fair value for its assets and liabilities: (a) Level 1—Quoted market prices in active markets for identical assets and liabilities (b) Level 2—Significant other observable inputs (e.g. quoted prices for similar items in active markets, quoted prices for identical or similar items in markets that are not active, inputs other than quoted prices that are observable, such as interest rate and yield curves, and market-corroborated inputs); and (c) Level 3—Unobservable inputs for the asset or liability, which are valued based on management's estimates of assumptions that market participants would use in pricing the asset or liability.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2015, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2015-11, "Inventory (Topic 330), Simplifying the Measurement of Inventory," which requires an entity to measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Currently, the inventory standard requires an entity to measure inventory at the lower of cost or market. Market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. The amendment does not apply to inventory that is measured using last-in, first-out (LIFO) or the retail inventory method but apply to all other inventory, which includes inventory that is measured using first-in, first-out (FIFO) or average cost. The amendment is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, and should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. Chemours is currently evaluating the impact of adopting this guidance. In May 2015, the FASB issued ASU No. 2015-07, "Fair Value Measurement (Topic 820) - Disclosures for Investment in Certain Entities that Calculate Net Asset Value per Share or its Equivalent." This guidance removes the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient. The guidance also removes the requirement to make certain disclosures for all investments that are eligible to be measured at fair value using the net asset value per share practical expedient. Rather, those disclosures are limited to investments for which the entity has elected to measure the fair value using that practical expedient. The amendment is effective for fiscal years beginning after December 15, 2015 and interim periods within those fiscal years. A reporting entity should apply the amendments retrospectively to all periods presented and earlier application is permitted. Chemours is currently evaluating the impact of adopting this guidance. In April 2015, the FASB issued ASU 2015-05, "Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement," which provides guidance about whether a cloud computing arrangement includes a software license. The customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If the cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. This guidance is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2015, and early adoption is permitted. Chemours is currently evaluating the impact of adopting this guidance. In April 2015, the FASB issued ASU No. 2015-03, “Interest — Imputation of Interest (Subtopic 835-30),” which requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The guidance is effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015 with early adoption permitted, including adoption in an interim period. Chemours adopted this guidance for the quarter ending June 30, 2015. The adoption of this standard has no impact on Chemours’ results of operations or cash flows. Due to the accounting change described above, Chemours recorded debt issuance costs incurred for the issuance of its senior secured term loans and senior unsecured notes as a reduction of the liability on the Interim Consolidated Balance Sheets. See Note 15 for additional information. In February 2015, the FASB issued ASU No. 2015-02, “Consolidation (Topic 810): Amendments to the Consolidation Analysis.” The amendments modify the evaluation of whether limited partnerships and similar legal entities are variable interest entities (VIEs) or voting interest entities and eliminate the presumption that a general partner should consolidate a limited partnership. The amendment is effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. A reporting entity also may apply the amendments retrospectively. Chemours is currently evaluating the impact of adopting this guidance on its financial position and results of operations. In May 2014, the FASB and the International Accounting Standards Board (IASB) jointly issued ASU No. 2014-09, "Revenue from Contracts with Customers (Topic 606)," which clarifies the principles for recognizing revenue and develops a common revenue standard for GAAP and International Financial Reporting Standards (IFRS). The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The guidance is effective for public entities for annual and interim periods beginning after December 15, 2016 (original effective date). In July 2015, the FASB approved a deferral of the effective date of this guidance to provide entities with adequate time to effectively implement the new revenue standard and adoption as of the original effective date is permitted. The Company is currently evaluating the impact of adopting this guidance on its financial position and results of operations. In April 2014, the FASB issued ASU No. 2014-08, “Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity,” amending existing requirements for reporting discontinued operations and disposals of components of an entity. The amended guidance limits the discontinued operations reporting to disposal transactions that represent strategic shifts having a major effect on operations and financial results. The amendment also enhances disclosures and requires assets and liabilities of a discontinued operation to be classified as such for all periods presented in the financial statements. Chemours adopted this guidance effective on January 1, 2015. Due to the change in requirements for reporting discontinued operations described above, presentation and disclosures of future disposal transactions after adoption may be different than under current standards.

- Definition

Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.

+ References + Details

Relationship with DuPont and Related Entities (Tables)

9 Months Ended

Sep. 30, 2015

Schedule of Related Party Transactions

Allocated leveraged functional service expenses and general corporate expenses were recorded in the Interim Consolidated Statements of Operations within the following captions:



	Three months ended September 30,					Nine months ended September 30,
	2015			2014		2015			2014
Selling, general and administrative expense	$	—	¹	$	105	$	205	¹	$	318
Research and development expense	—		¹	8		10		¹	35
Cost of goods sold	—		¹	8		23		¹	25
Total	$	—		$	121	$	238		$	378

Related party sales to DuPont include the following amounts:



Selling Segment	Three months ended September 30,					Nine months ended September 30,
Selling Segment	2015			2014		2015			2014
Titanium Technologies	$	—	¹	$	1	$	2	¹	$	1
Fluoroproducts	—		¹	10		34		¹	34
Chemical Solutions	—		¹	14		21		¹	55
Total	$	—		$	25	$	57		$	90

¹ Subsequent to the spin-off on July 1, 2015, transactions with DuPont businesses were not considered related party transactions.

Employee Separation and Asset Related Charges, Net (Tables)

9 Months Ended

Sep. 30, 2015

Restructuring Charges [Abstract]

Schedule of Restructuring Program

The following table shows the change in the liability account balance associated with our restructuring programs.



	Titanium Technologies Site Closures		Fluoroproducts		2015 Restructuring			2014 Restructuring			Total
Balance as of December 31, 2014	$	—	$	—	$	—		$	12		$	12
Charges to income for the nine months ended September 30, 2015	12		2		64			—			78
Charges to liability accounts:
Payments ¹	—		—		(23		)	(11		)	(34		)
Net currency translation adjustment ²	—		—		—			—			—
Balance as of September 30, 2015	$	12	$	2	$	41		$	1		$	56

²Net currency translation adjustment was less than $1 for all periods presented.

The charges related to our programs and impairments impacted 2015 segment earnings as follows:



For the three months ended September 30, 2015	Titanium Technologies	Fluoroproducts	Chemical Solutions	Total
Titanium Technologies Plant Closures	126	—	—	126
Fluoroproducts Restructuring	—	10	—	10
PP&E impairment ¹	—	—	45	45
2015 Restructuring	1	1	1	3
Total	127	11	46	184

¹ See Note 12 for further information.



For the nine months ended September 30, 2015	Titanium Technologies	Fluoroproducts	Chemical Solutions	Total
Titanium Technologies Plant Closures	126	—	—	126
Fluoroproducts Restructuring	—	10	—	10
PP&E impairment	—	—	45	45
2015 Restructuring	24	26	14	64	¹
Total	150	36	59	245

¹ Includes approximately $13 related to Corporate overhead functions that was allocated to our segments.



For the nine months ended September 30, 2014	Titanium Technologies		Fluoroproducts		Chemical Solutions		Total
2014 Restructuring	$	3	$	16	$	—	$	19

For the three and nine months ended, Chemours recorded charges for employee separation and asset related charges as follows:



	Three months ended September 30,				Nine months ended September 30,
	2015		2014		2015		2014
Employee Separation Charges	$	17	$	—	$	78	$	21
Asset Related Charges - Restructuring	122		—		122		—
Asset Related Charges - Impairment ¹	45		—		45		—
Total	$	184	$	—	$	245	$	21

¹ See Note 12 for further information.

Other Income, Net (Tables)

9 Months Ended

Sep. 30, 2015

Other Income and Expenses [Abstract]

Schedule of Other Income



	Three months ended September 30,					Nine months ended September 30,
	2015		2014			2015		2014
Leasing, contract services and miscellaneous income ¹	$	10	$	6		$	14	$	11
Royalty income²	3		13			10		22
Gain on sale of assets and businesses ³	—		1			—		12
Exchange gains (losses), net ⁴	44		(33		)	47		(29		)
Total other income, net	$	57	$	(13	)	$	71	$	16

¹Leasing, contract services and miscellaneous income includes accrued interest related to unrecognized tax benefits.

² Royalty income is primarily for technology and trademark licensing.

³Gain on sale of assets and businesses primarily relates to a sale of assets in the Fluoroproducts segment.

Accounts and Notes Receivable - Trade, Net (Tables)

9 Months Ended

Sep. 30, 2015

Receivables [Abstract]

Schedule of Accounts, Notes, Loans and Financing Receivable



	September 30, 2015		December 31, 2014
Accounts receivable—trade, net ¹	$	969	$	746
VAT, GST and other taxes ²	88		62
Advances and deposits	13		15
Leases receivable—current	13		12
Notes receivable—trade ³	19		11
Total	$	1,102	$	846

¹Accounts receivable – trade is net of allowances of $4 and $4 as of September 30, 2015 and December 31, 2014, respectively. Allowances are equal to the estimated uncollectible amounts.

²Value Added Tax (VAT) and Goods and Services Tax (GST) receivables are generally recorded at the legal entity level and allocated to Chemours within shared legal entities.

Earnings Per Share of Common Stock (Tables)

9 Months Ended

Sep. 30, 2015

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

The table below shows a reconciliation of the numerator and denominator for basic and diluted earnings per share calculations for the periods indicated.



	Three months ended September 30,						Nine months ended September 30,
	2015			2014			2015			2014
Numerator:
Income from continuing operations attributable to Chemours	$	(29	)	$	107	¹	$	(4	)	$	321	¹
Denominator:
Weighted-average number of common shares outstanding- Basic	180,968,049			180,966,833			180,968,049			180,966,833
Dilutive effect of the company's employee compensation plans²	—			—			—			—
Weighted average number of common shares outstanding - Diluted	180,968,049			180,966,833			180,968,049			180,966,833

¹ 2014 amounts do not reflect interest expense on approximately $4,003 of debt issued during the second quarter of 2015 in connection with the spin-off. See Note 15 for additional information.

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following average number of stock options were antidilutive and, therefore, were not included in the diluted earnings per share calculation:



	Three months ended September 30,		Nine months ended September 30,
	2015	2014	2015	2014
Average number of stock options	8,401,821	—	8,401,821	—

Inventories (Tables)

9 Months Ended

Sep. 30, 2015

Inventory, Net [Abstract]

Schedule of Inventories



	September 30, 2015			December 31, 2014
Finished products	$	662		$	611
Semi-finished products	186			173
Raw materials, stores and supplies	395			521
Subtotal	1,243			1,305
Adjustment of inventories to a last-in, first-out (LIFO) basis	(250		)	(253		)
Total	$	993		$	1,052

Goodwill and Intangible Assets, Net (Tables)

9 Months Ended

Sep. 30, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

The following table summarizes changes in the carrying amount of goodwill by reportable segment as of September 30, 2015:



	Titanium Technologies		Fluoroproducts		Chemical Solutions			Total
Balance as of December 31, 2014	$	13	$	85	$	100		$	198
Impairment charge	—		—		(25		)	(25		)
Other adjustments	—		—		(4		)	(4		)
Balance as of September 30, 2015	$	13	$	85	$	71		$	169

Schedule of Other Intangible Assets

The following table summarizes the gross carrying amounts and accumulated amortization of other intangible assets by major class:



	September 30, 2015							December 31, 2014
	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Customer lists	$	20	$	(17	)	$	3	$	19	$	(16	)	$	3
Patents	20		(17		)	3		20		(16		)	4
Purchased trademarks	18		(15		)	3		18		(14		)	4
Purchased and licensed technology	20		(18		)	2		17		(17		)	—
Total	$	78	$	(67	)	$	11	$	74	$	(63	)	$	11

Other Assets (Tables)

9 Months Ended

Sep. 30, 2015

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Schedule of Other Assets



	September 30, 2015		December 31, 2014
Leases receivable - non-current¹	$	128	$	137
Capitalized repair and maintenance costs	133		185
Pension assets ²	132		—
Advances and deposits	4		17
Deferred income taxes - non-current	30		9
Miscellaneous ³	39		27
Total	$	466	$	375

¹Leases receivable includes direct financing leases of property at two locations. See Note 10 for further information.

²Pension assets represent pension plans commencing in 2015. See Note 18 for further information.

Debt (Tables)

9 Months Ended

Sep. 30, 2015

Debt Disclosure [Abstract]

Schedule of Long-term Debt Instruments

Long-term debt, net of an unamortized discount on the Term Loan Facility of $7, was comprised of the following at September 30, 2015:



	September 30, 2015
Long-term debt:
Senior secured term loan, net of issue discount	$	1,489
Senior unsecured notes:
6.625%, due May 2023	1,350
7.00%, due May 2025	750
6.125%, due May 2023 (€360)	403
Other	26
Total	4,018
Less: Unamortized debt issuance costs	56
Less: Current maturities	38
Total long-term debt	$	3,924

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

+ Details

Financial Instruments (Tables)

9 Months Ended

Sep. 30, 2015

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Assets at Fair Value

The table below presents the fair value of Chemours’ derivative assets and liabilities within the fair value hierarchy, as described in Note 3 to the Interim Consolidated Financial Statements.



		Fair Value Using Level 2 Inputs
	Balance Sheet Location	September 30, 2015		December 31, 2014
Asset derivatives:
Foreign currency forward contracts	Accounts and notes receivable - trade, net	$	9	$	—
Total asset derivatives		$	9	$	—

Liability derivatives
Foreign currency forward contracts	Other accrued liabilities	$	3	$	—
Total liability derivatives		$	3	$	—

Schedule of Derivative Liabilities at Fair Value

The table below presents the fair value of Chemours’ derivative assets and liabilities within the fair value hierarchy, as described in Note 3 to the Interim Consolidated Financial Statements.



		Fair Value Using Level 2 Inputs
	Balance Sheet Location	September 30, 2015		December 31, 2014
Asset derivatives:
Foreign currency forward contracts	Accounts and notes receivable - trade, net	$	9	$	—
Total asset derivatives		$	9	$	—

Liability derivatives
Foreign currency forward contracts	Other accrued liabilities	$	3	$	—
Total liability derivatives		$	3	$	—

Long-Term Employee Benefits (Tables)

9 Months Ended

Sep. 30, 2015

General Discussion of Pension and Other Postretirement Benefits [Abstract]

Schedule of Multiemployer Plans

The following table presents the expense for DuPont’s significant plans in which Chemours participated prior to separation and are accounted for as multi-employer plans.



		Three months ended September 30,					Nine months ended September 30,
Plan Name	EIN / Pension Number	2015		2014			2015		2014
DuPont Pension and Retirement Plan (U.S.)	51-0014090/001	$	—	$	13		$	48	$	38
All other U.S. and non-U.S. Plans		—		(1		)	5		2

Schedule of Amounts Recognized in Other Comprehensive Income (Loss)

The pre-tax amounts recognized in accumulated other comprehensive (loss) income are summarized below:



Pension Benefits	September 30, 2015
Net loss	$	362
Prior service cost	(8		)
Total amount recognized in accumulated other comprehensive (loss) income	$	354

Schedules of Net Periodic Benefit Cost



Pension Benefits	Three Months Ended September 30, 2015			Nine Months Ended September 30, 2015
Components of net periodic pension cost:
Net periodic benefit (credit) cost:
Service cost	$	5		$	11
Interest cost	5			14
Expected return on plan assets	(21		)	(61		)
Amortization of loss	1			8
Amortization of prior service cost	4			6
Net periodic benefit (credit) cost	$	(6	)	$	(22	)

Schedule of Assumptions Used

The following assumptions have been used to determine the benefit obligations and net benefit cost:



Weighted average assumptions used to determine benefit obligations as of January 1, 2015 and benefit cost for the nine months ended September 30, 2015	Pension Benefit Obligations at January 1, 2015		Benefits Cost for the nine months ended September 30, 2015
Discount rate	2	%	3	%
Expected return on plan assets	7	%	7	%
Rate of compensation increase ¹	4	%	4	%

¹ The rate of compensation increase represents the single annual effective salary increase that an average plan participant would receive during the participant's entire career at Chemours.

Schedule of Allocation of Plan Assets



	Total			Level 1		Level 2
Asset Category:
Debt - government issued	$	553		$	24	$	529
Debt - corporate issued	150			52		98
Debt - asset backed	38			3		35
U.S. and non U.S. equities	538			52		486
Derivatives - asset position	33			—		33
Derivatives - liability position	(12		)	—		(12		)
Other	5			2		3
	1,305			$	133	$	1,172
Pension trust payables ¹	(17		)
Total	$	1,288

¹Primarily payables for investment securities purchased.

The weighted average target allocation for Chemours' pension plan assets is summarized as follows:



	January 1, 2015
U.S. equity securities	25	%
Non-U.S.equity securities	25	%
Fixed income securities	50	%
Total	100	%

Schedule of Expected Benefit Payments

The following benefit payments, which are related to non-U.S. plans that are predominantly Chemours and reflect future service, as appropriate, are expected to be paid:



Year ended December 31,	Benefits
Remainder of 2015	$	10
2016	44
2017	48
2018	47
2019	49
2020-2024	265

Segment Information (Tables)

9 Months Ended

Sep. 30, 2015

Segment Reporting [Abstract]

Schedule of Segment Information



Three months ended September 30,	Titanium Technologies		Fluoroproducts		Chemical Solutions		Corporate and Other			Total
2015
Sales	$	616	$	576	$	295	$	—		$	1,487
Less: Transfers	—		1		—		—			1
Net sales	$	616	$	575	$	295	$	—		$	1,486
Adjusted EBITDA	78		89		7		(5		)	$	169
Depreciation and amortization	32		23		14		1			70

2014
Sales	$	755	$	572	$	306	$	—		$	1,633
Less: Transfers	1		—		—		—			1
Net sales	$	754	$	572	$	306	$	—		$	1,632
Adjusted EBITDA	189		70		9		(33		)	235
Depreciation and amortization	29		16		12		—			57



Nine months ended September 30,	Titanium Technologies		Fluoroproducts		Chemical Solutions		Corporate and Other			Total
2015
Sales	$	1,804	$	1,716	$	839	$	—		$	4,359
Less: Transfers	1		1		—		—			2
Net sales	$	1,803	$	1,715	$	839	$	—		$	4,357
Adjusted EBITDA	262		218		12		(51		)	441
Depreciation and amortization	95		65		40		1			201

2014
Sales	$	2,254	$	1,752	$	882	$	—		$	4,888
Less: Transfers	5		—		—		—			5
Net sales	$	2,249	$	1,752	$	882	$	—		$	4,883
Adjusted EBITDA	563		209		16		(117		)	671
Depreciation and amortization	90		59		36		—			185

Reconciliation of EBITDA from Segments to Consolidated

Reconciliation to Consolidated Statements of Operations



	Three months ended September 30,						Nine months ended September 30,
	2015			2014			2015			2014
Total Adjusted EBITDA	$	169		$	235		$	441		$	671
Interest	(51		)	—			(79		)	—
Depreciation and amortization	(70		)	(57		)	(201		)	(185		)
Non-operating pension and other postretirement employee benefit costs	10			(3		)	(5		)	(18		)
Exchange gains (losses)	44			(33		)	47			(29		)
Asset impairments	(70		)	—			(70		)	—
Restructuring charges	(139		)	—			(200		)	(21		)
Gains (losses) on sale of business or assets	—			1			—			12
(Loss) income before income taxes	(107		)	143			(67		)	430
(Benefit from) provision for income taxes	(78		)	35			(63		)	108
Net (loss) income	$	(29	)	$	108		$	(4	)	$	322

Stock-based Compensation (Tables)

9 Months Ended

Sep. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Stock Options Valuation Assumptions

The expense related to stock options granted in the three and nine months ended September 30, 2015 was based on the assumptions shown in the table below.



Assumptions used to calculate expense for stock options	For the three and nine months ended September 30, 2015
Assumptions used to calculate expense for stock options	For the three and nine months ended September 30, 2015
Risk-free interest rate	1.5		%
Average life of options (years)	5.4
Volatility	42.0		%
Dividend yield	6.9		%
Fair value per stock option	$	3.17

Schedule of Stock Options Activity

The following table summarizes Chemours stock option activity for the three months ended September 30, 2015.



	Number of Shares (in thousands)		Weighted Average Exercise Price(per share)	Weighted Average Remaining Contractual Term (years)	Aggregate Intrinsic Value (in thousands)
Outstanding, June 30, 2015	—		N/A
Converted on July 1, 2015	7,793		14.56
Granted	662		16.04
Exercised	—		N/A
Forfeited	(107	)	17.16
Canceled	—		N/A
Outstanding, September 30, 2015	8.348		14.65	5.06	243
Exercisable, September 30, 2015	5,286		13.72	4.19	243

Schedule of Restricted Stock Units Activity

The weighted-average grant-date fair value of RSUs granted during 2015 was $14.94.



	Number of Shares (in thousands)		Weighted Average Grant Date Fair Value (per share)
Nonvested, June 30, 2015	—		—
Converted, July 1, 2015	1,438		16.00
Granted	1,065		13.50
Vested	(11	)	16.00
Forfeited	(13	)	16.00
Nonvested, September 30, 2015	2,479		14.94

Background and Description of the Business (Narrative) (Details)		9 Months Ended
	Jul. 01, 2015	Sep. 30, 2015 facility segment $ / shares	Jun. 23, 2015 $ / shares
Segment Reporting Information [Line Items]
Number of reportable segments \| segment		3
Number of facilities		36
Common stock , par value (USD per share) \| $ / shares		$ 0.01	$ 0.01
Spin off transaction distribution ratio	0.2
Parent Company [Member]
Segment Reporting Information [Line Items]
Common stock , par value (USD per share) \| $ / shares			$ 0.30
Operating Segments [Member]
Segment Reporting Information [Line Items]
Number of facilities		2
Titanium Technologies [Member]
Segment Reporting Information [Line Items]
Number of facilities		5
Fluoroproducts [Member]
Segment Reporting Information [Line Items]
Number of facilities		17
Chemical Solutions [Member]
Segment Reporting Information [Line Items]
Number of facilities		12

Basis of Presentation (Details) $ in Millions	9 Months Ended
Basis of Presentation (Details) $ in Millions	Sep. 30, 2015 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Noncash contribution	$ 93

Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014
Accounting Policies [Abstract]
Realized gains recognized in earnings, less than	$ 1	$ 1

Research and Development Expense (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development expense	$ 18	$ 33	$ 68	$ 110
Projects Incurred by Chemours [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development expense	18	25	58	75
Corporate Central Research and Development [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development expense	$ 0	$ 8	$ 10	$ 35

Relationship with DuPont and Related Entities (Related Party Purchases and Sales) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Related Party Transaction [Line Items]
Related party sales	$ 1	$ 1	$ 2	$ 5
Subsidiary of Common Parent [Member]
Related Party Transaction [Line Items]
Related party sales	0	25	57	90
Titanium Technologies [Member] \| Subsidiary of Common Parent [Member]
Related Party Transaction [Line Items]
Related party sales	0	1	2	1
Fluoroproducts [Member] \| Subsidiary of Common Parent [Member]
Related Party Transaction [Line Items]
Related party sales	0	10	34	34
Chemical Solutions [Member] \| Subsidiary of Common Parent [Member]
Related Party Transaction [Line Items]
Related party sales	$ 0	$ 14	$ 21	$ 55

Relationship with DuPont and Related Entities (Leveraged Services and Corporate Costs) (Details) - Affiliated Entity [Member] - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Related Party Transaction [Line Items]
Expenses from transactions with related party	$ 0	$ 121	$ 238	$ 378
Selling, General and Administrative Expenses [Member]
Related Party Transaction [Line Items]
Expenses from transactions with related party	0	105	205	318
Research and Development Expense [Member]
Related Party Transaction [Line Items]
Expenses from transactions with related party	0	8	10	35
Cost of Goods [Member]
Related Party Transaction [Line Items]
Expenses from transactions with related party	$ 0	$ 8	$ 23	$ 25

Relationship with DuPont and Related Entities (Details) $ in Millions	Sep. 30, 2015 USD ($)
DuPont [Member]
Related Party Transaction [Line Items]
Payable to DuPont	$ 49

Employee Separation and Asset Related Charges, Net Employee Separation and Assets Related Charges, Net (Charges) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Restructuring and Related Activities [Abstract]
Employee Separation Charges	$ 17	$ 0	$ 78	$ 21
Restructuring charges	122	0	122	0
Asset impairment charges	45	0	45	0
Employee separation and asset related charges, net	$ 184	$ 0	$ 245	$ 21

Employee Separation and Asset Related Charges, Net Employee Separation and Asset Related Charges, Net (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Restructuring Cost and Reserve [Line Items]
Expected adjusted EBITDA improvement	$ 500
Restructuring charges	122	$ 0	$ 122	$ 0
Asset impairment charges	45	0	45	0
Employee separation charges	17	$ 0	78	21
Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges			78
Titanium Technologies Site Closure [Member]
Restructuring Cost and Reserve [Line Items]
Asset impairment charges	114
Employee separation charges	12
Titanium Technologies Site Closure [Member] \| Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges			12
Fluroproducts Restructuring [Member] \| Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	2
Fluroproducts Restructuring [Member] \| Property, Plant and Equipment Accelerated Depreciation [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	8
2015 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	3
Expected cost remaining	41		41
2015 Restructuring Program [Member] \| Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges			64
2014 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges					$ 19
2014 Restructuring Program [Member] \| Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges			0		16
2014 Restructuring Program [Member] \| Asset Shut Down Charges [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges					$ 3
Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Asset impairment charges	45		45
Operating Segments [Member] \| Titanium Technologies Site Closure [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	126		126
Operating Segments [Member] \| Fluroproducts Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	10		10
Operating Segments [Member] \| 2015 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	3		64
Operating Segments [Member] \| 2014 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges				19
Titanium Technologies [Member] \| Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Asset impairment charges	0		0
Titanium Technologies [Member] \| Operating Segments [Member] \| Titanium Technologies Site Closure [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	126		126
Titanium Technologies [Member] \| Operating Segments [Member] \| Fluroproducts Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0		0
Titanium Technologies [Member] \| Operating Segments [Member] \| 2015 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 1		$ 24
Titanium Technologies [Member] \| Operating Segments [Member] \| 2014 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges				$ 3

Employee Separation and Asset Related Charges, Net (Segment Earnings) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 122	$ 0	$ 122	$ 0
Asset impairment charges	45	0	45	0
Employee separation and asset related charges, net	184	$ 0	245	21
Titanium Technologies [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	127
Fluoroproducts [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	11
Chemical Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges, net	46
Titanium Technologies Site Closure [Member]
Restructuring Cost and Reserve [Line Items]
Asset impairment charges	114
2015 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	3
2014 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges					$ 19
Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Asset impairment charges	45		45
Employee separation and asset related charges, net			245
Operating Segments [Member] \| Titanium Technologies [Member]
Restructuring Cost and Reserve [Line Items]
Asset impairment charges	0		0
Employee separation and asset related charges, net			150
Operating Segments [Member] \| Fluoroproducts [Member]
Restructuring Cost and Reserve [Line Items]
Asset impairment charges	0		0
Employee separation and asset related charges, net			36
Operating Segments [Member] \| Chemical Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Asset impairment charges	45		45
Employee separation and asset related charges, net			59
Operating Segments [Member] \| Titanium Technologies Site Closure [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	126		126
Operating Segments [Member] \| Titanium Technologies Site Closure [Member] \| Titanium Technologies [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	126		126
Operating Segments [Member] \| Titanium Technologies Site Closure [Member] \| Fluoroproducts [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0		0
Operating Segments [Member] \| Titanium Technologies Site Closure [Member] \| Chemical Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0		0
Operating Segments [Member] \| Fluroproducts Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	10		10
Operating Segments [Member] \| Fluroproducts Restructuring [Member] \| Titanium Technologies [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0		0
Operating Segments [Member] \| Fluroproducts Restructuring [Member] \| Fluoroproducts [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	10		10
Operating Segments [Member] \| Fluroproducts Restructuring [Member] \| Chemical Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0		0
Operating Segments [Member] \| 2015 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	3		64
Operating Segments [Member] \| 2015 Restructuring Program [Member] \| Titanium Technologies [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1		24
Operating Segments [Member] \| 2015 Restructuring Program [Member] \| Fluoroproducts [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1		26
Operating Segments [Member] \| 2015 Restructuring Program [Member] \| Chemical Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 1		14
Operating Segments [Member] \| 2014 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges				19
Operating Segments [Member] \| 2014 Restructuring Program [Member] \| Titanium Technologies [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges				3
Operating Segments [Member] \| 2014 Restructuring Program [Member] \| Fluoroproducts [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges				16
Operating Segments [Member] \| 2014 Restructuring Program [Member] \| Chemical Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges				$ 0
Corporate, Non-Segment [Member] \| 2015 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges			$ 13

Employee Separation and Asset Related Charges, Net (Restructuring Program schedule) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Restructuring Reserve [Roll Forward]
Restructuring charges	$ 122	$ 0	$ 122	$ 0
Net currency translation adjustment			1
2015 Restructuring Program [Member]
Restructuring Reserve [Roll Forward]
Restructuring charges	3
Payments	(15)		(23)
2014 Restructuring Program [Member]
Restructuring Reserve [Roll Forward]
Restructuring charges					$ 19
Payments	(2)		(11)
Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve			12
Restructuring charges			78
Payments			(34)
Net currency translation adjustment			0
Restructuring reserve	56		56		12
Employee Severance [Member] \| Titanium Technologies Site Closure [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve			0
Restructuring charges			12
Payments			0
Net currency translation adjustment			0
Restructuring reserve	12		12		0
Employee Severance [Member] \| Fluoroproducts [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve			0
Restructuring charges			2
Payments			0
Net currency translation adjustment			0
Restructuring reserve	2		2		0
Employee Severance [Member] \| 2015 Restructuring Program [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve			0
Restructuring charges			64
Payments			(23)
Net currency translation adjustment			0
Restructuring reserve	41		41		0
Employee Severance [Member] \| 2014 Restructuring Program [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve			12
Restructuring charges			0		16
Payments			(11)
Net currency translation adjustment			0
Restructuring reserve	$ 1		$ 1		$ 12

Other Income, Net (Schedule of Other Income) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Component of Other Income [Line Items]
Exchange gains (losses), net	$ 44	$ (33)	$ 47	$ (29)
Total other income, net	57	(13)	71	16
Exchange gains (losses),net	22		31
Foreign Exchange Contract [Member]
Component of Other Income [Line Items]
Gain on derivative	66		78
Other Income [Member]
Component of Other Income [Line Items]
Leasing, contract services and miscellaneous income	10	6	14	11
Royalty income	3	13	10	22
Gain on sale of assets and businesses	0	1	0	12
Exchange gains (losses), net	44	(33)	47	(29)
Total other income, net	$ 57	$ (13)	$ 71	$ 16

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Income Taxes (Details) - USD ($) $ in Millions	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Tax Disclosure [Abstract]
Provision (benefit) for income taxes	$ (78)	$ 35	$ (63)	$ 108
Unremitted earnings of foreign subsidiaries	$ 1,300		$ 1,300

Accounts and Notes Receivable - Trade, Net (Schedule of Accounts and Notes Receivable) (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Receivables [Abstract]
Accounts receivable—trade, net	$ 969	$ 746
VAT, GST and other taxes	88	62
Advances and deposits	13	15
Leases receivable—current	13	12
Notes receivable—trade	19	11
Total	$ 1,102	$ 846

Earnings Per Share of Common Stock (Earnings per Share Calculation) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	May 12, 2015
Numerator:
Income from continuing operations attributable to Chemours	$ (29,000,000)	$ 107,000,000	$ (4,000,000)	$ 321,000,000
Denominator:
Weighted-average number of common shares outstanding- Basic	180,968,049	180,966,833	180,968,049	180,966,833
Dilutive effect of the company's employee compensation plans	$ 0	$ 0	$ 0	$ 0
Weighted average number of common shares outstanding - Diluted	180,968,049	180,966,833	180,968,049	180,966,833
Long-term debt, gross					$ 4,003,000,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Accounts and Notes Receivable - Trade, Net (Narrative) (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2015 USD ($)	Sep. 30, 2014 USD ($)	Sep. 30, 2015 USD ($) facility	Sep. 30, 2014 USD ($)	Dec. 31, 2014 USD ($)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for doubtful accounts receivable	$ 4,000,000		$ 4,000,000		$ 4,000,000
Bad debt expense, less than	1,000,000	$ 1,000,000	$ 1,000,000	$ 1,000,000
Number of facilities with fixed assets constructed on land \| facility			2
Leases receivable	141,000,000		$ 141,000,000		$ 149,000,000
Estimated future residual value of leased assets	0		0
Notes Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Derivative assets	$ 9,000,000		$ 9,000,000

Earnings Per Share of Common Stock (Antidilutive Shares Excluded from Computation of Earnings per Share) (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Earnings Per Share [Abstract]
Average number of stock options	8,401,821	0	8,401,821	0

Inventories (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Inventory, Net [Abstract]
Finished products	$ 662	$ 611
Semifinished products	186	173
Raw materials, stores and supplies	395	521
Total inventories before LIFO adjustment	1,243	1,305
Adjustment of inventories to a last-in, first-out (LIFO) basis	(250)	(253)
Total	993	1,052
LIFO inventory amount	$ 719	$ 684
Percentage of LIFO inventory	58.00%	52.00%

Property, Plant, and Equipment Property, Plant and Equipment (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Depreciation and amortization	$ 69	$ 56	$ 198	$ 183
Capital leased assets	7		7		$ 6
Asset impairment charges	$ 45	$ 0	$ 45	$ 0

Goodwill and Intangible Assets, Net Goodwill and Intangible Assets, Net (Schedule of Goodwill) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Goodwill [Roll Forward]
Goodwill, beginning balance			$ 198
Impairment charge	$ (25)	$ 0	(25)	$ 0
Other Adjustments			(4)
Goodwill, ending balance	169		169
Chemical Solutions [Member]
Goodwill [Roll Forward]
Impairment charge	(25)
Operating Segments [Member] \| Titanium Technologies [Member]
Goodwill [Roll Forward]
Goodwill, beginning balance			13
Impairment charge			0
Other Adjustments			0
Goodwill, ending balance	13		13
Operating Segments [Member] \| Fluroproducts [Member]
Goodwill [Roll Forward]
Goodwill, beginning balance			85
Impairment charge			0
Other Adjustments			0
Goodwill, ending balance	85		85
Operating Segments [Member] \| Chemical Solutions [Member]
Goodwill [Roll Forward]
Goodwill, beginning balance			100
Impairment charge			(25)
Other Adjustments			(4)
Goodwill, ending balance	$ 71		$ 71

Goodwill and Intangible Assets, Net (Narrative) (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015 USD ($) segment	Sep. 30, 2014 USD ($)	Sep. 30, 2015 USD ($) segment	Sep. 30, 2014 USD ($)
Goodwill and Other Intangible Assets
Number of operating segments			3
Number of reportable segments			3
Impairment charge \| $	$ 25	$ 0	$ 25	$ 0
Minimum [Member]
Goodwill and Other Intangible Assets
Useful life			5 years
Maximum [Member]
Goodwill and Other Intangible Assets
Useful life			20 years
Continuing Operations [Member]
Goodwill and Other Intangible Assets
Aggregate pre-tax amortization expense \| $	$ 1	$ 1	$ 3	$ 2
Chemical Solutions [Member]
Goodwill and Other Intangible Assets
Number of reportable segments for purposes of goodwill	7
Impairment charge \| $	$ 25
Fluroproducts [Member]
Goodwill and Other Intangible Assets
Number of reportable segments			1

Goodwill and Intangible Assets, Net (Schedule of Other Intangible Assets) (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Definite-lived Intangible Assets, Gross	$ 78	$ 74
Definite-lived Intangible Assets, Accumulated Amortization	(67)	(63)
Definite-lived Intangible Assets, Net	11	11
Customer Lists [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Definite-lived Intangible Assets, Gross	20	19
Definite-lived Intangible Assets, Accumulated Amortization	(17)	(16)
Definite-lived Intangible Assets, Net	3	3
Patents [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Definite-lived Intangible Assets, Gross	20	20
Definite-lived Intangible Assets, Accumulated Amortization	(17)	(16)
Definite-lived Intangible Assets, Net	3	4
Trademarks [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Definite-lived Intangible Assets, Gross	18	18
Definite-lived Intangible Assets, Accumulated Amortization	(15)	(14)
Definite-lived Intangible Assets, Net	3	4
Purchased and Licensed Technology [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Definite-lived Intangible Assets, Gross	20	17
Definite-lived Intangible Assets, Accumulated Amortization	(18)	(17)
Definite-lived Intangible Assets, Net	$ 2	$ 0

Other Assets (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Leases receivable - non-current	$ 128	$ 137
Capitalized repair and maintenance costs	133	185
Pension assets	132	0
Advances and deposits	4	17
Deferred income taxes - non-current	30	9
Miscellaneous	39	27
Total	466	375
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Deferred financing fee	$ 22	$ 22

Debt (Components of Long-Term Debt) (Details) € in Millions, $ in Millions	Sep. 30, 2015 USD ($)	Sep. 30, 2015 EUR (€)	May 12, 2015 USD ($)	May 12, 2015 EUR (€)	Dec. 31, 2014 USD ($)
Debt Instrument [Line Items]
Long-term debt, gross			$ 4,003
Long-term debt	$ 4,018
Less: Unamortized debt issuance costs	56
Less: Current maturities	38				$ 0
Total long-term debt	3,924				$ 0
Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt, gross			2,503
Senior Notes [Member] \| 6.625% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Long-term debt, gross			1,350
Long-term debt	$ 1,350
Debt instrument interest rate	6.625%	6.625%
Senior Notes [Member] \| 7.00% Senior Notes Due May 2025 [Member]
Debt Instrument [Line Items]
Long-term debt, gross			750
Long-term debt	$ 750
Debt instrument interest rate	7.00%	7.00%
Senior Notes [Member] \| Senior Notes 6.125% Due May 2023 [Member]
Debt Instrument [Line Items]
Long-term debt, gross \| €		€ 360		€ 360
Long-term debt	$ 403
Debt instrument interest rate	6.125%	6.125%
Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Long-term debt	$ 26
The Term Loan Facility [Member]
Debt Instrument [Line Items]
Unamortized discount	7		$ 7
Long-term debt	$ 1,489
Debt instrument interest rate	1.00%	1.00%

Debt (Senior Secured Credit Facilities) (Details)	9 Months Ended
Debt (Senior Secured Credit Facilities) (Details)	Sep. 30, 2015 USD ($)	May 12, 2015 USD ($)
Domestic Subsidiary [Member]
Line of Credit Facility [Line Items]
Collateral as percentage of common stock	100.00%
Foreign Subsidiary [Member]
Line of Credit Facility [Line Items]
Collateral as percentage of common stock	65.00%
The Term Loan Facility [Member]
Line of Credit Facility [Line Items]
Debt instrument term	7 years
Line of credit facility, maximum borrowing capacity		$ 1,500,000,000
Periodic payment, percentage of face amount	1.00%
Unamortized discount	$ 7,000,000	7,000,000
Stated percentage rate, minimum	3.75%
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Debt instrument term	5 years
Line of credit facility, maximum borrowing capacity		$ 1,000,000,000
Letters of credit outstanding	$ 129,000,000
Commitment fee percentage	0.30%
Leverage ratio maximum	3.00
Revolving Credit Facility [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Unused capacity commitment fee percentage	0.20%
Revolving Credit Facility [Member] \| Maximum [Member]
Line of Credit Facility [Line Items]
Unused capacity commitment fee percentage	0.35%
Revolving Credit Facility [Member] \| Base Rate [Member]
Line of Credit Facility [Line Items]
Variable rate	1.00%
Revolving Credit Facility [Member] \| Base Rate [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Variable rate	0.50%
Revolving Credit Facility [Member] \| Base Rate [Member] \| Maximum [Member]
Line of Credit Facility [Line Items]
Variable rate	1.25%
Revolving Credit Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Variable rate	2.00%
Revolving Credit Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Variable rate	1.50%
Revolving Credit Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member] \| Maximum [Member]
Line of Credit Facility [Line Items]
Variable rate	2.25%

Debt (Senior Unsecured Notes) (Details) € in Millions	9 Months Ended
Debt (Senior Unsecured Notes) (Details) € in Millions	Sep. 30, 2015 USD ($)	Sep. 30, 2015 EUR (€)	May 12, 2015 USD ($)	May 12, 2015 EUR (€)
Debt Instrument [Line Items]
Long-term debt, gross			$ 4,003,000,000
Long-term debt	$ 4,018,000,000
Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt, gross			2,503,000,000
Debt Instrument, interest rate, additional	0.25%	0.25%
Threshold consecutive days following registration default	90 days
Threshold consecutive days following registration default, additional	90 days
Debt Instrument, interest rate additional maximum	0.50%	0.50%
Senior Notes [Member] \| 6.625% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Long-term debt, gross			1,350,000,000
Long-term debt	$ 1,350,000,000
Senior Notes [Member] \| 7.00% Senior Notes Due May 2025 [Member]
Debt Instrument [Line Items]
Long-term debt, gross			750,000,000
Long-term debt	750,000,000
Debt Instrument, face amount			$ 507,000,000
Senior Notes [Member] \| Senior Notes 6.125% Due May 2023 [Member]
Debt Instrument [Line Items]
Long-term debt, gross \| €		€ 360		€ 360
Long-term debt	$ 403,000,000

Debt (Maturities and Fair Value) (Details) $ in Millions	9 Months Ended
Debt (Maturities and Fair Value) (Details) $ in Millions	Sep. 30, 2015 USD ($)
Debt Instrument [Line Items]
Years with no long term debt maturities	7 years
Senior Notes [Member] \| 6.625% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.625%
Senior Notes [Member] \| 7.00% Senior Notes Due May 2025 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	7.00%
Senior Notes [Member] \| Senior Notes 6.125% Due May 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.125%
Fair Value, Inputs, Level 2 [Member] \| Senior Notes [Member] \| 6.625% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Notes, fair value	$ 906
Fair Value, Inputs, Level 2 [Member] \| Senior Notes [Member] \| 7.00% Senior Notes Due May 2025 [Member]
Debt Instrument [Line Items]
Notes, fair value	494
Fair Value, Inputs, Level 2 [Member] \| Senior Notes [Member] \| Senior Notes 6.125% Due May 2023 [Member]
Debt Instrument [Line Items]
Notes, fair value	$ 268
The Term Loan Facility [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	1.00%
2015	$ 4
2016	15
2017	15
2018	15
2019	15
2020	15
2021 and beyond	3,920
The Term Loan Facility [Member] \| Fair Value, Inputs, Level 2 [Member]
Debt Instrument [Line Items]
Line of credit facility, fair value	$ 1,362

Commitments and Contingent Liabilities (Guarantees) (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Guarantee obligations	$ 9	$ 41

Commitments and Contingent Liabilities (Litigation) (Narrative) (Details) resident in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2015 USD ($) lawsuit	Dec. 31, 2005 USD ($)	Dec. 31, 2004 resident	Dec. 31, 2014 USD ($)	Sep. 30, 2014 plantiff	Jan. 31, 2012 USD ($)
Loss Contingencies [Line Items]
Loss contingency, potential additional loss	$ 630,000,000
Funding for medical monitoring program [Member]
Loss Contingencies [Line Items]
Escrow deposit disbursements	$ 1,000,000
Asbestos Issue [Member]
Loss Contingencies [Line Items]
Lawsuits alleging personal injury - Filed \| lawsuit	2,360
Accrual balance	$ 38,000,000			$ 38,000,000
Asbestos Issue [Member] \| Non-US [Member]
Loss Contingencies [Line Items]
Accrual balance	$ 2,000,000
Benzene Related Illness [Member]
Loss Contingencies [Line Items]
Lawsuits alleging illness \| lawsuit	28
Years of exposure to benzene	24 years
Compensatory damages awarded	$ 6,900,000
Punitive damages awarded	1,500,000
PFOA Matters [Member]
Loss Contingencies [Line Items]
Accrual balance	14,000,000			$ 14,000,000
PFOA Matters: Drinking Water Actions [Member]
Loss Contingencies [Line Items]
Binding settlement agreement, class size \| resident			80
PFOA Matters: Drinking Water Actions [Member] \| Payment for Plaintiffs Attorney Fees [Member]
Loss Contingencies [Line Items]
Settlement payments		$ 23,000,000
PFOA Matters: Drinking Water Actions [Member] \| Payment to fund community health project [Member]
Loss Contingencies [Line Items]
Settlement payments		$ 70,000,000
PFOA Matters: Drinking Water Actions [Member] \| Funding for medical monitoring program [Member]
Loss Contingencies [Line Items]
Loss contingency, potential additional loss	$ 235,000,000
Escrow deposit						$ 1,000,000
PFOA Matters: Additional Actions [Member]
Loss Contingencies [Line Items]
Lawsuits alleging personal injury - Filed \| lawsuit	3,500
Lawsuits alleging wrongful death \| lawsuit	37
PFOA MDL Plaintiffs selected for individual trial \| plantiff					6
Damages awarded due to negligence	$ 1,100,000
Damages awarded due to emotional distress	$ 500,000

Commitments and Contingent Liabilities (Environmental) (Narrative) (Details)	9 Months Ended
	Sep. 30, 2015 USD ($) a
Environmental Remediation [Line Items]
Accrual for environmental remediation activities	$ 300,000,000
Loss contingency, potential additional loss	630,000,000
Pompton Lakes [Member] \| Lead and Mercury Emissions [Member]
Environmental Remediation [Line Items]
Accrual for environmental remediation activities	88,000,000
Loss contingency, potential additional loss	$ 119,000,000
Area of lake \| a	36
Environmental remediation expense	$ 50,000,000
Minimum [Member]
Environmental Remediation [Line Items]
Average time frame of disbursements of environmental site remediation	15 years
Minimum [Member] \| Pompton Lakes [Member] \| Lead and Mercury Emissions [Member]
Environmental Remediation [Line Items]
Average time frame of disbursements of environmental site remediation	2 years
Maximum [Member]
Environmental Remediation [Line Items]
Average time frame of disbursements of environmental site remediation	20 years
Maximum [Member] \| Pompton Lakes [Member] \| Lead and Mercury Emissions [Member]
Environmental Remediation [Line Items]
Average time frame of disbursements of environmental site remediation	3 years

Financial Instruments (Details) € in Millions, $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2015 USD ($) contract	Sep. 30, 2015 USD ($) contract	Sep. 30, 2015 EUR (€) contract	May 12, 2015 USD ($)	May 12, 2015 EUR (€)	Dec. 31, 2014 contract
Derivative [Line Items]
Long-term debt, gross				$ 4,003
Senior Notes [Member]
Derivative [Line Items]
Long-term debt, gross				$ 2,503
Senior Notes 6.125% Due May 2023 [Member] \| Senior Notes [Member]
Derivative [Line Items]
Long-term debt, gross \| €			€ 360		€ 360
Designated as Hedging Instrument [Member]
Derivative [Line Items]
Recognized gains on derivative net investment hedge, less than	$ 1	$ 1
Foreign Exchange Contract [Member]
Derivative [Line Items]
Number of forward exchange currency contracts \| contract	64	64	64			0
Derivative notional value	$ 1,030	$ 1,030
Foreign Exchange Contract [Member] \| Not Designated as Hedging Instrument [Member] \| Other Income [Member]
Derivative [Line Items]
Derivative gain	$ 66	$ 78

Financial Instruments (Schedule of the Fair Value of Derivative Instruments) (Details) - Fair Value, Measurements, Recurring [Member] - Fair Value, Inputs, Level 2 [Member] - Not Designated as Hedging Instrument [Member] - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Derivatives, Fair Value [Line Items]
Asset derivatives	$ 9	$ 0
Liability derivatives	3	0
Foreign Exchange Contract [Member] \| Trade Accounts Receivable [Member]
Derivatives, Fair Value [Line Items]
Asset derivatives	9	0
Foreign Exchange Contract [Member] \| Accrued Liabilities and Other Liabilities [Member]
Derivatives, Fair Value [Line Items]
Liability derivatives	$ 3	$ 0

Long Term Employee Benefits Defined Benefit Plans (Narrative) (Details) - Parent Company [Member]	9 Months Ended
	Sep. 30, 2015
Defined Benefit Plan Disclosure [Line Items]
Employer matching contribution percent of match	100.00%
Employer matching contribution percent of employees' gross pay	6.00%
Employer discretionary contribution percent of employees' gross pay	3.00%
Employer contribution vesting period	3 years

Long-Term Employee Benefits (Mulitemployer Plan) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
DuPont Pension and Retirement Plan (U.S.) [Member]
Multiemployer Plans [Line Items]
Pension and other postretirement benefit expense	$ 0	$ 13	$ 48	$ 38
Other U.S. and non-U.S. Plans [Member]
Multiemployer Plans [Line Items]
Pension and other postretirement benefit expense	$ 0	$ (1)	$ 5	$ 2

Long-Term Employee Benefits (Single and Multiple Employer Plans) (Details) - Foreign Pension Plan [Member] - USD ($) $ in Millions	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Jun. 30, 2015	Sep. 30, 2015	Dec. 31, 2014	Jan. 01, 2015
Pension Benefits
Net loss	$ 362		$ 362
Prior service cost	(8)		(8)
Total amount recognized in accumulated other comprehensive (loss) income	354		354
Accumulated benefit obligation					$ 1,186
Benefit obligation					1,309
Fair value of plan assets, net of plan liabilities					1,288
Fair value of plan assets					$ 1,305
Amount to be amortized from accumulated other comprehensive income (loss) in next fiscal year			5
Parent Company [Member]
Pension Benefits
Contributions by employer	$ 4	$ 38		$ 35
Parent Company [Member] \| Taiwan [Member]
Pension Benefits
Contributions by employer			$ 28

Long-Term Employee Benefits (Schedules of Net Periodic Benefit Cost) (Details) - Foreign Pension Plan [Member] - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2015
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 5	$ 11
Interest cost	5	14
Expected return on plan assets	(21)	(61)
Amortization of loss	1	8
Amortization of prior service cost	4	6
Net periodic benefit cost	$ (6)	$ (22)

Long-Term Employee Benefits (Assumptions) (Details) - Foreign Pension Plan [Member]		9 Months Ended
	Jan. 01, 2015	Sep. 30, 2015
Defined Benefit Plan Disclosure [Line Items]
Discount rate	2.00%	3.00%
Expected return on plan assets	7.00%	7.00%
Rate of compensation increase	4.00%	4.00%

Long-Term Employee Benefits (Plan Assets) (Details) - Foreign Pension Plan [Member] $ in Millions	Jan. 01, 2015 USD ($)
Defined Benefit Plan Disclosure [Line Items]
Target plan asset allocations	100.00%
Fair value of plan assets	$ 1,305
Fair value of plan liabilities	(17)
Fair value of plan assets, net of plan liabilities	1,288
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	133
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 1,172
U.S. Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Target plan asset allocations	25.00%
Non U.S. Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Target plan asset allocations	25.00%
Fixed Income Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Target plan asset allocations	50.00%
US Treasury and Government [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 553
US Treasury and Government [Member] \| Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	24
US Treasury and Government [Member] \| Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	529
Corporate Debt Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	150
Corporate Debt Securities [Member] \| Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	52
Corporate Debt Securities [Member] \| Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	98
Asset-backed Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	38
Asset-backed Securities [Member] \| Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3
Asset-backed Securities [Member] \| Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	35
Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	538
Equity Securities [Member] \| Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	52
Equity Securities [Member] \| Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	486
Derivatives Financial Instruments, Assets [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	33
Derivatives Financial Instruments, Assets [Member] \| Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0
Derivatives Financial Instruments, Assets [Member] \| Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	33
Derivative Financial Instruments, Liabilities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	(12)
Derivative Financial Instruments, Liabilities [Member] \| Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0
Derivative Financial Instruments, Liabilities [Member] \| Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	(12)
Other Plan Assets [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	5
Other Plan Assets [Member] \| Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	2
Other Plan Assets [Member] \| Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 3

Long-Term Employee Benefits (Cash Flow) (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Jun. 30, 2015	Sep. 30, 2015	Dec. 31, 2014
Foreign Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Estimated future employer contributions in current fiscal year			$ 4
Defined Benefit Plan, Expected Future Benefit Payments, Fiscal Year Maturity [Abstract]
Remainder of 2015	$ 10		10
2016	44		44
2017	48		48
2018	47		47
2019	49		49
2020-2024	265		$ 265
Foreign Pension Plan [Member] \| Parent Company [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions by employer	$ 4	$ 38		$ 35
Other Long-Term Employee Benefit Plans [Member] \| Parent Company [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions by employer				$ 66

Segment Information (Narrative) (Details)	9 Months Ended
Segment Information (Narrative) (Details)	Sep. 30, 2015 segment
Segment Reporting [Abstract]
Number of reportable segments	3

Stock-based Compensation (Details) - USD ($) $ / shares in Units, $ in Millions		3 Months Ended		9 Months Ended
	Jul. 01, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation cost		$ 8.0	$ 2.0	$ 13.0	$ 6.0
Income tax benefit		3.0	$ 1.0	5.0	$ 2.0
Conversion of stock incremental cost	$ 3.0
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to stock options		$ 5.0		$ 5.0
Unrecognized compensation cost period for recognition				2 years 1 month 10 days
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost period for recognition				2 years 2 months 19 days
Stock-based compensation award vesting period				3 years
Restricted stock units nonvested, weighted average grant date fair value		$ 14.94		$ 14.94		$ 0.00
Unrecognized compensation cost related to restricted stock units		$ 28.0		$ 28.0
Minimum [Member] \| Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation award vesting period				2 years
Maximum [Member] \| Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation award vesting period				5 years

Segment Information (Schedule of Segment Information) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Segment sales	$ 1,487	$ 1,633	$ 4,359	$ 4,888
Less: Transfers	1	1	2	5
Net sales	1,486	1,632	4,357	4,883
Adjusted EBITDA	169	235	441	671
Depreciation and amortization	70	57	201	185
Corporate, Non-Segment [Member]
Segment sales	0	0	0	0
Less: Transfers	0	0	0	0
Net sales	0	0	0	0
Adjusted EBITDA	(5)	(33)	(51)	(117)
Depreciation and amortization	1	0	1	0
Titanium Technologies [Member] \| Operating Segments [Member]
Segment sales	616	755	1,804	2,254
Less: Transfers	0	1	1	5
Net sales	616	754	1,803	2,249
Adjusted EBITDA	78	189	262	563
Depreciation and amortization	32	29	95	90
Fluoroproducts [Member] \| Operating Segments [Member]
Segment sales	576	572	1,716	1,752
Less: Transfers	1	0	1	0
Net sales	575	572	1,715	1,752
Adjusted EBITDA	89	70	218	209
Depreciation and amortization	23	16	65	59
Chemical Solutions [Member] \| Operating Segments [Member]
Segment sales	295	306	839	882
Less: Transfers	0	0	0	0
Net sales	295	306	839	882
Adjusted EBITDA	7	9	12	16
Depreciation and amortization	$ 14	$ 12	$ 40	$ 36

Stock-based Compensation (Stock Option Assumptions) (Details) - Employee Stock Option [Member]	9 Months Ended
	Sep. 30, 2015 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.50%
Average life of options (years)	5 years 4 months 24 days
Volatility	42.00%
Dividend yield	6.90%
Fair value per stock option	$ 3.17

Segment Information (Reconciliation to Consolidated Income Statements) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Segment Reporting [Abstract]
Total Adjusted EBITDA	$ 169	$ 235	$ 441	$ 671
Interest	(51)	0	(79)	0
Depreciation and amortization	(70)	(57)	(201)	(185)
Non-operating pension and other postretirement employee benefit costs	10	(3)	(5)	(18)
Exchange gains (losses)	44	(33)	47	(29)
Asset impairments	(70)	0	(70)	0
Restructuring charges	(139)	0	(200)	(21)
Gains (losses) on sale of business or assets	0	1	0	12
(Loss) income before income taxes	(107)	143	(67)	430
(Benefit from) provision for income taxes	(78)	35	(63)	108
Net (loss) income	$ (29)	$ 108	$ (4)	$ 322

Stock-based Compensation (Stock Option Activity) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Sep. 30, 2015	Jul. 01, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Options converted, weighted average exercise price		$ 14.56
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options outstanding, number of shares, beginning balance	0
Options converted, number of shares		7,793
Options granted, number of shares	662
Options exercised, number of shares	0
Options forfeited, number of shares	(107)
Options canceled, number of shares	0
Options outstanding, number of shares, ending balance	8,348.000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Options granted, weighted average exercise price	$ 16.04
Options forfeited, weighted average exercise price	17.16
Options outstanding, weighted average exercise price, ending balance	$ 14.65
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options exercisable, number of shares	5,286
Options exercisable, weighted average exercise price	$ 13.72
Options outstanding, weighted average remaining contractual term	5 years 22 days
Options exercisable, weighted average remaining contractual term	4 years 2 months 9 days
Options outstanding, aggregate intrinsic value	$ 243
Options exercisable, aggregate intrinsic value	$ 243

Stock-based Compensation (Restricted Stock Units) (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares shares in Thousands	3 Months Ended
	Sep. 30, 2015	Jul. 01, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Restricted stock units nonvested, number of shares, beginning balance	0
Restricted stock units converted, number of shares		1,438
Restricted stock units granted, number of shares	1,065
Restricted stock units vested, number of shares	(11)
Restricted stock units forfeited, number of shares	(13)
Restricted stock units nonvested, number of shares, ending balance	2,479
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Restricted stock units nonvested, weighted average grant date fair value, beginning balance	$ 0.00
Restricted stock units converted, weighted average grant date fair value		$ 16.00
Restricted stock units granted, weighted average grant date fair value	13.50
Restricted stock units vested, weighted average grant date fair value	16.00
Restricted stock units forfeitures, weighted average grant date fair value	16.00
Restricted stock units nonvested, weighted average grant date fair value, ending balance	$ 14.94